Pharmaceutical composition and application thereof
Patent Information
- Application Number
- CN202480014828.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-03-10
- Filing Date
- 2024-03-08
- Publication Date
- 2025-10-10
AI Technical Summary
Existing technology is difficult to effectively reduce low-density lipoprotein cholesterol (LDL-c) levels in plasma, and siRNA that inhibits APOC3 or PCSK9 alone cannot significantly reduce LDL-c.
The combination of an RNAi agent for APOC3 mRNA and an RNAi agent for PCSK9 mRNA in a specific ratio was used to synergistically reduce total cholesterol and LDL-c levels in plasma.
It significantly reduces total cholesterol and LDL-c levels in plasma, surpassing the effect of using siRNA alone, demonstrating a strong synergistic effect, and has good application prospects in the treatment and prevention of hyperlipidemia-related diseases.
Smart Images

Figure CN120769912A_ABST
Abstract
Description
A pharmaceutical composition and its use Technical Field
[0001] The present disclosure relates to a pharmaceutical composition capable of treating and / or preventing diseases or symptoms associated with hyperlipidemia, the present disclosure also relates to uses of the pharmaceutical composition and a method for treating and / or preventing diseases or symptoms associated with hyperlipidemia. Background Art
[0002] Dyslipidemia, also known as hyperlipidemia, is a systemic disease characterized by abnormal fat metabolism or operation, causing plasma lipids to be higher than normal. Among them, persistently high low-density lipoprotein cholesterol (LDL-c) is an important risk factor for inducing and promoting the occurrence and development of atherosclerosis. It is closely related to ischemic cardiovascular and cerebrovascular diseases and is a serious threat to the health of patients worldwide.
[0003] Studies have shown that apolipoprotein C3 (APOC3) plays a crucial role in lipid metabolism. In individuals with APOC3 mutations, circulating APOC3 expression is reduced by 46%, and plasma triglyceride levels are 39% lower than those of the general population. The proprotein convertase subtilisin / kexin type 9 (PCSK9) gene plays a crucial role in lipid metabolism, particularly cholesterol metabolism. Inhibiting the expression of the PCSK9 and / or APOC3 genes can effectively lower plasma total cholesterol (TC) levels.
[0004] Therefore, using small interfering RNA (siRNA) to silence gene expression at the genetic level and block APOC3 and PCSK9 is undoubtedly an ideal approach for treating dyslipidemia. However, current studies have found that using siRNA to inhibit APOC3 or PCSK9 alone, even with increasing doses, is difficult to lower LDL-c to very low levels.
[0005] Summary of the Invention
[0006] The inventors of the present disclosure unexpectedly discovered that the combination of an RNAi agent capable of inhibiting APOC3 mRNA and an RNAi agent capable of inhibiting PCSK9 mRNA in a specific ratio or dosage for the prevention and / or treatment of diseases or symptoms associated with hyperlipidemia exhibits a high synergistic effect, not only being able to reduce plasma TC levels, but also being able to stably and significantly reduce plasma LDL-c levels over a long period of time, demonstrating an excellent therapeutic effect.
[0007] In one aspect, the present disclosure provides a pharmaceutical composition comprising a first RNAi agent and a second RNAi agent, wherein the first RNAi agent comprises one or more first siRNAs and / or one or more first siRNA conjugates, each first siRNA is independently an siRNA capable of inhibiting APOC3 mRNA, and each first siRNA conjugate comprises an siRNA group formed by one of the first siRNAs and a conjugated group conjugated thereto;
[0008] The second RNAi agent comprises one or more second siRNAs and / or one or more second siRNA conjugates, each second siRNA is independently an siRNA capable of inhibiting PCSK9 mRNA, and each second siRNA conjugate comprises an siRNA group formed by one second siRNA species and a conjugated group conjugated thereto;
[0009] Based on the total amount of siRNA and siRNA groups contained in each of the first RNAi agent and the second RNAi agent, the weight ratio of the first RNAi agent to the second RNAi agent in the pharmaceutical composition is 10:1-1:10.
[0010] In yet another aspect, the present disclosure further provides use of the pharmaceutical composition of the present disclosure in preparing a medicament for treating and / or preventing diseases or symptoms associated with hyperlipidemia.
[0011] In yet another aspect, the present disclosure further provides a method for treating and / or preventing a disease or symptom associated with hyperlipidemia, the method comprising administering a first RNAi agent and a second RNAi agent to a subject in need thereof, wherein the first RNAi agent comprises one or more first siRNAs and / or one or more first siRNA conjugates, each first siRNA being independently an siRNA capable of inhibiting APOC3 mRNA, and each first siRNA conjugate comprising an siRNA group formed by one of the first siRNAs and a conjugated group conjugated thereto;
[0012] The second RNAi agent comprises one or more second siRNAs and / or one or more second siRNA conjugates, each second siRNA is an siRNA capable of inhibiting PCSK9 mRNA, and each second siRNA conjugate comprises an siRNA group formed by one second siRNA species and a conjugated group conjugated thereto;
[0013] The weight ratio of the first RNAi agent and the second RNAi agent administered to the subject is 10:1-1:10, based on the total amount of siRNA and siRNA groups contained in each of the first RNAi agent and the second RNAi agent.
[0014] Incorporated by reference
[0015] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. Beneficial effects
[0016] Compared to administering a single RNAi agent that inhibits APOC3 mRNA or a single RNAi agent that inhibits PCSK9 mRNA, the compositions and treatment methods provided herein exhibit significantly greater reduction effects on both TC and LDL-c levels, demonstrating significant synergy. In particular, they demonstrate a strong synergistic effect on the highly sought-after reduction of LDL-c levels, unexpectedly surpassing the LDL-c reduction limits achieved by administering the first or second RNAi agent alone. The pharmaceutical compositions and treatment methods disclosed herein have promising application prospects for preventing and / or treating symptoms or diseases associated with hyperlipidemia.
[0017] Regarding the changes in TC levels, on the one hand, under the condition that the total dose was 6 mg / Kg, the TC in mice that were administered with 6 mg / Kg of RNAi agent that inhibits PCSK9 mRNA alone showed almost no decrease, while the mice that were administered with the pharmaceutical composition of the present invention (3 mg / Kg each of RNAi agent that inhibits APOC3 mRNA and RNAi agent that inhibits PCSK9 mRNA) showed a TC reduction rate of more than 45% (TC reduction rate = 100% - TC content normalized value); even if the TC reduction rates in the mice in the groups that were administered with RNAi agent that inhibits APOC3 mRNA and RNAi agent that inhibits PCSK9 mRNA were added together, the TC reduction rate was less than 45%; under the condition that the total dose was 4 mg / Kg, the mice that were administered with 1 mg / Kg of RNAi agent that inhibits APOC3 mRNA and 3 mg / Kg of RNAi agent that inhibits PCSK9 mRNA alone showed a TC reduction rate of more than 45%. The maximum total TC reduction rate in mice in the group of RNAi agents that inhibit mRNA was 34.9%, while the TC reduction rate in mice administered with the pharmaceutical composition of the present invention (1 mg / Kg RNAi agent that inhibits APOC3 mRNA and 3 mg / Kg RNAi agent that inhibits PCSK9 mRNA) reached 37.2%. On the other hand, taking the change in TC level on the 8th day after administration as an example, under the condition that the total dose was 6 mg / Kg, the group that was administered with 6 mg / Kg of RNAi agent that inhibits PCSK9 mRNA alone did not show a decrease in TC, while the group that was administered with the pharmaceutical composition of the present invention (RNAi agent that inhibits APOC3 mRNA and RNAi agent that inhibits PCSK9 mRNA, each 3 mg / Kg) showed a TC reduction rate of 45.6%; and the sum of the TC reduction rates of the group that was administered with RNAi agent that inhibits APOC3 mRNA (3 mg / Kg) and the group that was administered with RNAi agent that inhibits PCSK9 mRNA (3 mg / Kg) was only 33.3%; under the condition that the total dose was 4 mg / Kg, the group 1 that was administered with 1 mg / Kg of RNAi agent that inhibits APOC3 mRNA alone and the group 3 mg / Kg that inhibits PCSK9 mRNA alone showed a decrease in TC. The combined TC reduction rate of the groups treated with RNAi agents that inhibit APOC3 mRNA was the highest at 34.9%, while the TC reduction rate of the group administered with the pharmaceutical composition of the present disclosure (1 mg / Kg of RNAi agent that inhibits APOC3 mRNA and 3 mg / Kg of RNAi agent that inhibits PCSK9 mRNA) reached 37.0%.
[0018] Regarding changes in LDL-c levels, at a total dose of 6 mg / kg, mice administered with a PCSK9 mRNA-inhibiting RNAi agent alone showed a maximum LDL-c reduction rate of 43.3% (LDL-c reduction rate = 100% - LDL-c content normalized value), while mice administered with the pharmaceutical composition of the present disclosure showed an LDL-c reduction rate of up to 72.8%. Furthermore, neither high-dose RNAi agents that inhibit APOC3 mRNA nor high-dose RNAi agents that inhibit PCSK9 mRNA alone could reduce plasma LDL-c levels to below 50%, while mice administered with a low dose (4 mg / kg) of the pharmaceutical composition of the present disclosure showed an LDL-c reduction rate of up to 67%. Taking the changes in LDL-c levels on the 8th day after administration as an example, under the condition that the total administration dose was 6 mg / Kg, the group that was administered with the RNAi agent that inhibited PCSK9 mRNA alone showed an LDL-c reduction rate of 41.4%, while the group that was administered with the pharmaceutical composition of the present invention (3 mg / Kg each of the RNAi agent that inhibited APOC3 mRNA and the RNAi agent that inhibited PCSK9 mRNA) showed an LDL-c reduction rate of up to 72.8%. DETAILED DESCRIPTION
[0019] The following describes the specific embodiments of the present disclosure in detail. It should be understood that the specific embodiments described herein are only used to illustrate and explain the present disclosure, and are not intended to limit the present disclosure.
[0020] In the present disclosure, unless otherwise specified, APOC mRNA or “mRNA expressed by the APOC3 gene” refers to mRNA having the sequence shown in Genbank Accession No. NM_000040.3, and the APOC3 gene refers to the gene that transcribes the above-mentioned APOC3 mRNA; PCSK9 mRNA or “mRNA expressed by the PCSK9 gene” refers to mRNA having the sequence shown in Genbank Accession No. NM_174936.3, and the PCSK9 gene refers to the gene that transcribes the above-mentioned PCSK9 mRNA; ANGPTL3 mRNA or “mRNA expressed by the ANGPTL3 gene” refers to mRNA having the sequence shown in Genbank Accession No. NM_014495.4, and the ANGPTL3 gene refers to the gene that transcribes the above-mentioned ANGPTL3 mRNA.
[0021] definition
[0022] In the above and below, unless otherwise specified, the capital letters C, G, U, and A represent the base composition of the nucleotide; the lowercase letter m indicates that the nucleotide adjacent to the left of the letter m is a methoxy-modified nucleotide; the lowercase letter f indicates that the nucleotide adjacent to the left of the letter f is a fluorine-modified nucleotide; the lowercase letter s indicates that the two nucleotides adjacent to the left and right of the letter s are connected by a phosphorothioate group; P1 indicates that the nucleotide adjacent to the right of P1 is a 5'-phosphate nucleotide or a 5'-phosphate analogue-modified nucleotide. In some embodiments, P1 is VP, Ps, or P representing a specific modification, wherein the letter combination VP indicates that the nucleotide adjacent to the right of the letter combination VP is a vinyl phosphate (5'-(E)-vinylphosphonate, E-VP)-modified nucleotide, the letter combination Ps indicates that the nucleotide adjacent to the right of the letter combination Ps is a phosphorothioate-modified nucleotide, the capital letter P indicates that the nucleotide adjacent to the right of the letter P is a 5'-phosphate nucleotide, and the underlined capital letter S indicates that the nucleotide adjacent to the left of the letter S is a stabilized modified nucleotide. Each U base and T base in all sequences disclosed herein can be replaced with each other without significantly affecting the activity or off-target effects of the siRNA disclosed herein.
[0023] In the above and below, the "fluoro-modified nucleotide" refers to a nucleotide in which the hydroxyl group at the 2' position of the ribose group of the nucleotide is replaced by fluorine, and the "non-fluorinated modified nucleotide" refers to a nucleotide or nucleotide analog in which the hydroxyl group at the 2' position of the ribose group of the nucleotide is replaced by a non-fluorinated group. These nucleotides in which the hydroxyl group at the 2' position of the ribose group is replaced by a non-fluorinated group are well known to those skilled in the art. These nucleotides can be selected from one of 2'-alkoxy-modified nucleotides, 2'-alkyl-modified nucleotides, 2'-substituted alkyl-modified nucleotides, 2'-amino-modified nucleotides, 2'-substituted amino-modified nucleotides, and 2'-deoxynucleotides. In some embodiments, the 2'-alkoxy-modified nucleotide can be a methoxy-modified nucleotide. "Methoxy-modified nucleotide" refers to a nucleotide in which the 2'-hydroxyl group of the ribose group is replaced by a methoxy group. "Nucleotide analog" refers to a group that can replace a nucleotide in a nucleic acid but has a structure different from that of adenine ribonucleotides, guanine ribonucleotides, cytosine ribonucleotides, uracil ribonucleotides or thymine deoxyribonucleotides. Such as isonucleotides, bridged nucleic acids (BNA) or acyclic nucleotides.
[0024] In some embodiments, the "non-fluorinated modified nucleotide" may also be a stabilizing modified nucleotide, wherein the stabilizing modified nucleotide refers to a nucleotide in which the 2'-hydroxyl group of the ribose sugar of the nucleotide is replaced by a stabilizing modifying group, and the thermal stability of the siRNA comprising the stabilizing modified nucleotide is increased compared to the siRNA in which the nucleotide at the corresponding position is an unmodified nucleotide. The stabilizing modified nucleotide refers to a nucleotide in which the 2'-hydroxyl group of the ribose sugar of the nucleotide is replaced by a stabilizing modifying group, and the thermal stability of the siRNA comprising the stabilizing modified nucleotide is increased compared to the siRNA in which the nucleotide at the corresponding position is an unmodified nucleotide. In some embodiments, the stabilizing modifying group is selected from one or more of 2'-O-methoxyethyl, 2'-O-allyl, 2'-C-allyl, 2'-O-2-N-methylamino-2-oxyylideneethyl, 2'-O-2-N,N-dimethylaminoethyl, 2'-O-3-aminopropyl, and 2'-O-2,4-dinitrophenyl.
[0025] In the context of this article, the expressions "complementary" and "reverse complementary" are used interchangeably and have the meanings known to those skilled in the art, i.e., in a double-stranded nucleic acid molecule, the bases of one strand are paired with bases on the other strand in a complementary manner. In DNA, the purine base adenine (A) is always paired with the pyrimidine base thymine (T) (or uracil (U) in RNA); the purine base guanine (C) is always paired with the pyrimidine base cytosine (G). Each base pair consists of a purine and a pyrimidine. When adenine on one strand is always paired with thymine (or uracil) on the other strand, and guanine is always paired with cytosine, the two strands are considered to be complementary to each other, and the sequence of the strand can be inferred from the sequence of its complementary strand. Accordingly, "mismatch" means in the art that the bases at corresponding positions in a double-stranded nucleic acid are not paired in a complementary manner.
[0026] In the above and below, unless otherwise specified, "substantially reverse complementary" means that there are no more than 3 base mismatches between the two nucleotide sequences involved; "substantially reverse complementary" means that there is no more than 1 base mismatch between the two nucleotide sequences; and "completely reverse complementary" means that there is no base mismatch between the two nucleotide sequences.
[0027] In the above and below, particularly when describing the preparation method of siRNA of the present disclosure, pharmaceutical composition or siRNA conjugate, unless otherwise stated, described nucleoside monomer (nucleoside monomer) refers to, according to the kind and order of nucleotide in the siRNA for preparation or the siRNA conjugate, the modification used in phosphoramidite solid phase synthesis or unmodified nucleoside phosphoramidite monomer (unmodified or modified RNA phosphoramidites, RNA phosphoramidites is also referred to as Nucleoside phosphoramidites sometimes).Phosphoramidite solid phase synthesis is the method used in RNA synthesis known to those skilled in the art.The nucleoside monomer used in the disclosure all can be commercially obtained.
[0028] It will be understood by those skilled in the art that for any group comprising one or more substituents, these groups are not intended to introduce any substitution or substitution pattern that is sterically impractical, synthetically infeasible, and / or inherently unstable.
[0029] As used herein, "alkyl" refers to straight and branched chains having a specified number of carbon atoms, typically 1 to 20 carbon atoms, for example 1 to 10 carbon atoms, such as 1 to 8 or 1 to 6 carbon atoms. For example, C1-C6 alkyl includes straight and branched chain alkyl groups of 1 to 6 carbon atoms. When referring to an alkyl residue having a specific number of carbons, it is intended to encompass all branched and straight chain forms having that number of carbons; thus, for example, "butyl" is meant to include n-butyl, sec-butyl, isobutyl, and tert-butyl; "propyl" includes n-propyl and isopropyl. Alkylene is a subset of alkyl and refers to a residue that is the same as alkyl, but has two points of attachment.
[0030] As used herein, "alkenyl" refers to an unsaturated branched or straight chain alkyl group having at least one carbon-carbon double bond, wherein the carbon-carbon double bond is obtained by removing a molecule of hydrogen from the adjacent carbon atoms of the parent alkyl group. The group can be in the cis or trans configuration of the double bond. Typical alkenyl groups include, but are not limited to, vinyl; propenyl, such as prop-1-ene-1-yl, prop-1-ene-2-yl, prop-2-ene-1-yl (allyl), prop-2-ene-2-yl; butenyl, such as but-1-ene-1-yl, but-1-ene-2-yl, 2-methylprop-1-ene-1-yl, but-2-ene-1-yl, but-2-ene-2-yl, but-1,3-diene-1-yl, but-1,3-diene-2-yl, etc. In certain embodiments, the alkenyl group has 2 to 20 carbon atoms, and in other embodiments, has 2 to 10, 2 to 8, or 2 to 6 carbon atoms. Alkenylene is a subset of alkenyl and refers to residues identical to alkenyl but with two points of attachment.
[0031] As used herein, "alkynyl" refers to an unsaturated branched or straight chain alkyl group having at least one carbon-carbon triple bond, obtained by removing two molecules of hydrogen from adjacent carbon atoms of a parent alkyl group. Typical alkynyl groups include, but are not limited to, ethynyl; propynyl, such as prop-1-yn-1-yl, prop-2-yn-1-yl; butynyl, such as but-1-yn-1-yl, but-1-yn-3-yl, but-3-yn-1-yl, and the like. In certain embodiments, alkynyl groups have 2 to 20 carbon atoms, and in other embodiments, have 2 to 10, 2 to 8, or 2 to 6 carbon atoms. Alkynylene is a subset of alkynyl and refers to residues that are identical to alkynyl, but with two points of attachment.
[0032] As used herein, "alkoxy" refers to an alkyl group of the specified number of carbon atoms attached through an oxygen bridge, for example, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, pentoxy, 2-pentoxy, isopentoxy, neopentoxy, hexoxy, 2-hexyloxy, 3-hexyloxy, 3-methylpentoxy, etc. The alkoxy group typically has 1 to 10, 1 to 8, 1 to 6, or 1 to 4 carbon atoms attached through the oxygen bridge.
[0033] As used herein, "aryl" refers to a radical derived from an aromatic monocyclic or polycyclic hydrocarbon ring system by removing hydrogen atoms from ring carbon atoms. The aromatic monocyclic or polycyclic hydrocarbon ring system contains only hydrogen and carbon of 6 to 18 carbon atoms, wherein at least one ring in the ring system is fully unsaturated, i.e., contains a cyclic, delocalized (4n+2)π-electron system according to Hückel's theory. Aryl includes, but is not limited to, radicals such as phenyl, fluorenyl, and naphthyl. Arylene is a subset of aryl and refers to residues identical to aryl but having two points of attachment.
[0034] "Heteroaryl" refers to a group derived from a 5- to 18-membered aromatic ring radical, comprising 2 to 17 carbon atoms and 1 to 6 heteroatoms selected from nitrogen, oxygen, and sulfur. As used herein, a heteroaryl group can be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, wherein at least one ring in the ring system is fully unsaturated, i.e., comprises a cyclic delocalized (4n+2)π-electron system according to Hückel theory. Heteroaryl groups include fused or bridged ring systems. In some embodiments, the heteroatom in the heteroaryl group is an oxidized heteroatom. In some embodiments, the heteroaryl group comprises one or more nitrogen atoms. In some embodiments, one or more of the nitrogen atoms in the heteroaryl group is a quaternized nitrogen atom. The heteroaryl group is attached to the remainder of the molecule through any ring atom. Examples of heteroaryl groups include, but are not limited to, azacycloheptatrienyl, acridinyl, benzimidazolyl, benzindolyl, 1,3-benzodioxazolyl, benzofuranyl, benzoxazolyl, benzo[d]thiazolyl, benzothiadiazolyl, benzo[b][1,4]dioxepinyl, benzo[b][1,4]oxazinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyrone, benzofuranyl, benzofuranone, benzothiophenyl, benzothieno[3,2-d]pyrimidinyl, benzotriazole yl, benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl, cinnolinyl, cyclopenta[d]pyrimidinyl, 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinyl, 5,6-dihydrobenzo[h]quinazolinyl, 5,6-dihydrobenzo[h]quinazolinyl yl (5,6dihydrobenzo[h]cinnolinyl), 6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, furanone, furano[3,2-c]pyridinyl, 5,6,7,8,9,10-hexahydrocycloocta[d]pyrimidinyl, 5,6,7,8,9,10-hexahydrocycloocta[d]pyrimidinyl, pyridazinyl, 5,6,7,8,9,10-hexahydrocyclooctanol[d]pyridinyl, isothiazolyl, imidazolyl, indazolyl, indolyl, isoindolyl, dihydroindolinyl, isoindolinyl, isoquinolinyl, indolizinyl, isoxazolyl, 5,8-methano-5,6,7,8-tetrahydroquinazolinyl (5,8-methano-5,6,7,8-tetrahydroquinazolinyl),8-tetrahydroquinazolinyl), naphthyl, 1,6-naphthyl-onyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl, 5,6,6a,7,8,9,10,10a-octahydrobenzo[H]quinazolinyl, 1-phenyl-1H-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyrazolo[3,4-d]pyrimidinyl, pyridinyl, pyrido[3,2-d]pyrimidinyl, pyrido[3,4-d]pyrimidinyl, ]pyrimidinyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrrolyl, quinazolinyl, quinoxalinyl, quinolinyl, tetrahydroquinolinyl, 5,6,7,8-tetrahydroquinazolinyl, 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinyl, 6,7,8,9-tetrahydro-5H-cyclohepta[4,5]thieno[2,3-d]pyrimidinyl, 5,6,7,8-tetrahydropyrido[4,5-c]pyridazinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl, thieno[2,3-d]pyrimidinyl, thieno[3,2-d]pyrimidinyl, thieno[2,3-c]pridinyl, and thiophenyl / thienyl. ,
[0035] Various hydroxy protecting groups can be used in the present disclosure. In general, protecting groups make chemical functionality insensitive to specific reaction conditions and can be added and removed on the functionality in the molecule without substantially damaging the rest of the molecule. Representative hydroxy protecting groups are disclosed in Beaucage et al., Tetrahedron 1992, 48, 2223-2311, and Greene and Wuts, Protective Groups in Organic Synthesis, Chapter 2, 2d ed, John Wiley & Sons, New York, 1991, each of which is incorporated herein by reference in its entirety. In some embodiments, the protecting group is stable under alkaline conditions, but can be removed under acidic conditions. In some embodiments, non-exclusive examples of hydroxy protecting groups that can be used herein include dimethoxytrityl (DMT), monomethoxytrityl, 9-phenylxanthen-9-yl (Pixyl) and 9-(p-methoxyphenyl)xanthen-9-yl (Mox). In some embodiments, non-exclusive examples of hydroxy protecting groups that may be used herein include Tr (trityl), MMTr (4-methoxytrityl), DMTr (4,4'-dimethoxytrityl), and TMTr (4,4',4"-trimethoxytrityl).
[0036] The term "subject," as used herein, refers to any animal, such as a mammal or marsupial. Subjects of the present disclosure include, but are not limited to, humans, non-human primates (e.g., rhesus monkeys or other types of macaques), mice, pigs, horses, donkeys, cattle, rabbits, sheep, rats, and any type of poultry.
[0037] Pharmaceutical compositions of the present disclosure
[0038] In one aspect, the present disclosure provides a pharmaceutical composition that can treat and / or prevent diseases or symptoms associated with hyperlipidemia. As used herein, "treatment" refers to a method of obtaining a beneficial or desired result, including but not limited to a therapeutic benefit. "Therapeutic benefit" means eradicating or improving the underlying disorder being treated. In addition, a therapeutic benefit is obtained by eradicating or improving one or more physiological symptoms associated with the underlying disorder, thereby observing improvement in the subject, even though the subject may still be suffering from the underlying disorder.
[0039] As used herein, "prevention" refers to a method of obtaining a beneficial or desired result, including but not limited to a preventive benefit. In order to obtain a "preventive benefit", the pharmaceutical composition of the present disclosure can be administered to a subject at risk of developing a particular disease, or to a subject reporting one or more physiological symptoms of a disease, even though a diagnosis of the disease may not yet be made. The "prevention of a disease or symptom associated with hyperlipidemia" refers to the prevention of an increase in blood lipids in the subject's body to an abnormal level by administering the pharmaceutical composition of the present disclosure to the subject when the subject begins to show a tendency to increase blood lipids, wherein the abnormal level refers to a total cholesterol (TC) level exceeding 6.2 mmol / L, a triglyceride (TG) level exceeding 2.3 mmol / L, and / or a low-density lipoprotein cholesterol (LDL-C) level exceeding 4.1 mmol / L in the human subject's body.
[0040] The pharmaceutical composition of the present disclosure comprises a first RNAi agent and a second RNAi agent, wherein the first RNAi agent comprises one or more first siRNAs and / or one or more first siRNA conjugates, each first siRNA being independently an siRNA capable of inhibiting APOC3 mRNA, and each first siRNA conjugate comprising an siRNA group formed by one of the first siRNAs and a conjugated group conjugated thereto.
[0041] The second RNAi agent comprises one or more second siRNAs and / or one or more second siRNA conjugates, each second siRNA being independently an siRNA capable of inhibiting PCSK9 mRNA, and each second siRNA conjugate comprising an siRNA group formed by one second siRNA species and a conjugated group conjugated thereto.
[0042] In the context of the present disclosure, unless otherwise specified, "conjugation" refers to the connection between two or more chemical moieties, each of which has a specific function, in a covalently linked manner; accordingly, "conjugate" refers to a compound formed by covalently linking the chemical moieties. Further, "siRNA conjugate" means a compound formed by covalently linking one or more chemical moieties with specific functions to siRNA. siRNA conjugates should be understood as a general term for multiple siRNA conjugates or an siRNA conjugate shown by a certain chemical formula, depending on the context. In the context of the present disclosure, "conjugated molecule" should be understood as a specific compound that can be conjugated to siRNA through a reaction to ultimately form a siRNA conjugate. As used in the present disclosure, "siRNA conjugate" comprises an siRNA group and a conjugated group portion, wherein the siRNA group refers to a chemical portion formed after removing one or more atoms from the siRNA molecule. It will be understood by those skilled in the art that the removal of one or more of the above atoms will not destroy the inhibitory activity or stability of the siRNA against the target mRNA. For example, the siRNA group can be a chemical part formed by removing the hydrogen atom in the phosphate bond of the siRNA, or the chemical part formed by removing the hydrogen atom in the 5' hydroxyl group of the 5' terminal nucleotide of the sense strand or antisense strand of the siRNA, or the chemical part formed by removing the hydrogen atom in the 3' hydroxyl group of the 3' terminal nucleotide of the sense strand or antisense strand of the siRNA.
[0043] Based on the total amount of siRNA and siRNA groups contained in each of the first and second RNAi agents, the weight ratio of the first RNAi agent to the second RNAi agent in the pharmaceutical composition is 100:1-1:100, for example, 100:1, 50:1, 25:1, 15:1, 10:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:100, 1:50, 1:25, 1:15, 1:10, 1:5, 1:3, 1:4, 1:2. In some embodiments, preferably, the weight ratio of the first RNAi agent to the second RNAi agent in the pharmaceutical composition is 10:1-1:10, 5:1-1:5 or 2:1-1:5. In some embodiments, in order to obtain a better therapeutic / preventive effect, the weight of the second RNAi agent is not less than the weight of the first RNAi agent, and the weight ratio of the first RNAi agent to the second RNAi agent in the pharmaceutical composition is 1:1-1:10, 1:1-1:5 or 1:1-1:3.
[0044] In some embodiments, the weight of the first RNAi agent in the pharmaceutical composition is 1 mg-1000 mg, for example, 1 mg-800 mg, 1 mg-600 mg, 1 mg-500 mg, 1 mg-300 mg, 1 mg-250 mg, or 1 mg-100 mg, based on the total amount of siRNA and siRNA groups contained in each of the first and second RNAi agents. In some embodiments, the weight of the first RNAi agent is 5 mg-500 mg.
[0045] In some embodiments, the weight of the second RNAi agent is 1 mg-1000 mg, for example, 1 mg-800 mg, 1 mg-600 mg, 1 mg-500 mg, 1 mg-300 mg, 1 mg-250 mg, or 1 mg-100 mg. In some embodiments, the weight of the first RNAi agent in the pharmaceutical composition is 5 mg-500 mg, and in some embodiments, the weight of the second RNAi agent is 5 mg-800 mg.
[0046] In some embodiments, the pharmaceutical composition further comprises a third RNAi agent, comprising one or more third siRNAs and / or one or more third siRNA conjugates, each of the third siRNAs being independently an siRNA capable of inhibiting ANGPTL3 mRNA expression, and each of the third siRNA conjugates comprising a third siRNA group formed from one of the third siRNAs and a conjugated group conjugated thereto. In some embodiments, the third RNAi agent and the first and / or second RNAi agent can further enhance the therapeutic and / or preventive effects of the pharmaceutical composition of the present disclosure on diseases and / or symptoms associated with hyperlipidemia.
[0047] In some embodiments, the weight of the third RNAi agent and the second RNAi agent is calculated based on the total amount of siRNA and siRNA groups contained in each of the third RNAi agent and the second RNAi agent, and the weight ratio of the third RNAi agent to the second RNAi agent in the pharmaceutical composition is 100:1-1:100, for example, 100:1, 50:1, 25:1, 15:1, 10:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:100, 1:50, 1:25, 1:15, 1:10, 1:5, 1:3, 1:4, 1:2. In some embodiments, preferably, the weight ratio of the third RNAi agent and the second RNAi agent in the pharmaceutical composition is 10:1-1:10, 5:1-1:5, or 2:1-1:5.
[0048] In some embodiments, the weight of the third RNAi agent is 1 mg-1000 mg, for example, 1 mg-800 mg, 1 mg-600 mg, 1 mg-500 mg, 1 mg-300 mg, 1 mg-250 mg, or 1 mg-100 mg. In some embodiments, the weight of the third RNAi agent in the pharmaceutical composition is 5 mg-500 mg, and in some embodiments, the weight of the third RNAi agent is 5 mg-800 mg.
[0049] First RNAi agent
[0050] As described above, the pharmaceutical composition of the present disclosure comprises a first RNAi agent. The first RNAi agent comprises one or more first siRNAs and / or one or more first siRNA conjugates, each first siRNA being independently an siRNA capable of inhibiting APOC3 mRNA, and each first siRNA conjugate comprising an siRNA group formed by one of the first siRNAs and a conjugated group conjugated thereto.
[0051] The siRNA capable of inhibiting APOC3 mRNA can be any siRNA capable of inhibiting APOC3 mRNA. In some embodiments, each first siRNA comprises a sense strand and an antisense strand, and each nucleotide in the sense strand and the antisense strand is independently a modified or unmodified nucleotide; wherein the sense strand is 18-23 nucleotides in length, and the antisense strand is 18-26 nucleotides in length, and the sense strand and the antisense strand are substantially reverse complementary or completely reverse complementary. The first siRNA includes at least one siRNA, and the sense strand of the first siRNA is identical to the nucleotide sequence of SEQ ID NO: 1 for at least 15 consecutive nucleotides, or the sense strand is identical to the nucleotide sequence of SEQ ID NO: 2 for at least 15 consecutive nucleotides.
[0052] 5'-UGGCCUCCCAAUAAAGCUGGACAAGAAGCU-3' (SEQ ID NO: 1);
[0053] 5'-UGCUUAAAAGGGACAGUAUUCUCAGUGCUC-3' (SEQ ID NO: 2).
[0054] In some embodiments, the sense strand is identical to the nucleotide sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 2 for at least 15, 16, 17, 18, or 19 consecutive nucleotides. In some embodiments, in the 5'-3' direction, the sense strand comprises a nucleotide sequence that is identical to nucleotides 9-27 of the nucleotide sequence set forth in SEQ ID NO: 1, or a nucleotide sequence that is identical to nucleotides 4-22 of the nucleotide sequence set forth in SEQ ID NO: 2.
[0055] The lengths of the sense strand and the antisense strand in the first siRNA may be the same or different. In some embodiments, the length ratio of the sense strand and the antisense strand of the first siRNA may be 19 / 19, 19 / 20, 19 / 21, 19 / 22, 19 / 23, 19 / 24, 19 / 25, 19 / 26, 20 / 20, 20 / 21, 20 / 22, 20 / 23, 20 / 24 , 20 / 25, 20 / 26, 21 / 20, 21 / 21, 21 / 22, 21 / 23, 21 / 24, 21 / 25, 21 / 26, 22 / 20, 22 / 21, 22 / 22, 22 / 23, 22 / 24, 22 / 25, 22 / 26, 23 / 20, 23 / 21, 23 / 22, 23 / 23, 23 / 24, 23 / 25 or 23 / 26. For example, the length ratio is "19 / 19" which means that the length of the sense strand and the antisense strand are both 19 nucleotides; a length ratio of "19 / 21" means that the length of the sense strand is 19 nucleotides and the length of the antisense strand is 21 nucleotides, and so on. In some embodiments, the length ratio of the first siRNA sense strand to the antisense strand is 19 / 21, 21 / 23 or 23 / 25.
[0056] In some embodiments, in the first siRNA, some nucleotides in the sense strand and the antisense strand are modified nucleotides, and some nucleotides are unmodified nucleotides. In some embodiments, in the first siRNA, all nucleotides in the sense strand and the antisense strand are modified nucleotides; from the 5' end to the 3' end, the 7th to 9th nucleotides of the sense strand are 2'-fluoro-modified nucleotides, and from the 5' end to the 3' end, the 2nd, 6th, 14th, and 16th nucleotides of the antisense strand are 2'-fluoro-modified nucleotides, and the other nucleotides in the antisense strand are each independently one of non-fluoro-modified nucleotides.
[0057] In some embodiments, the first siRNA can be, for example, any of the siRNAs listed in Table 1a and Table 1b. SiRNA conjugates comprising or formed from these siRNAs exhibit high APOC3 mRNA inhibitory activity. To achieve a better inhibitory effect, in some embodiments, the first siRNA has a sequence such as siAPOC3b1-M1SP1 and / or siAPOC3b3-M1S.
[0058] Table 1a Sequence of the first siRNA
[0059] Table 1b Sequence of the first siRNA
[0060] Among them, the capital letters C, G, U, and A represent the base composition of the nucleotide; the lowercase letter m indicates that the nucleotide adjacent to the left of the letter m is a methoxy-modified nucleotide; the lowercase letter f indicates that the nucleotide adjacent to the left of the letter f is a fluorinated modified nucleotide; the underlined capital letter S indicates that the nucleotide adjacent to the left of the letter S is a stabilizing modified nucleotide; the lowercase letter s indicates that the two nucleotides to the left of the letter s are connected by a phosphorothioate group; P1 indicates that the nucleotide adjacent to the right of P1 is a 5'-phosphate nucleotide or a 5'-phosphate analog modified nucleotide. In some embodiments, S represents a specific stabilizing modification such as moe, and the underlined letter combination moe indicates that the nucleotide adjacent to the left of the letter combination moe is a nucleotide with a 2'-O-methoxyethyl modification. In some embodiments, P1 represents a specific modification of VP, Ps, or P, wherein the letter combination VP indicates that the nucleotide immediately to the right of the letter combination VP is a 5'-(E)-vinylphosphonate (E-VP)-modified nucleotide, the letter combination Ps indicates that the nucleotide immediately to the right of the letter combination Ps is a phosphorothioate-modified nucleotide, and the capital letter P indicates that the nucleotide immediately to the right of the letter P is a 5'-phosphate nucleotide. Furthermore, each U in the sequences listed in Tables 1a-1c above can be arbitrarily replaced with a T without significantly affecting the activity or off-target effects of the siRNA.
[0061] In some embodiments, the conjugated group in each of the first siRNA conjugates comprises a linker and a pharmaceutically acceptable targeting group and / or a delivery auxiliary group, and the first siRNA group, the linker and the targeting group or the delivery auxiliary group are covalently or non-covalently linked in sequence, each of the targeting groups is selected from a ligand capable of binding to a cell surface receptor, and each of the delivery auxiliary groups is selected from a group capable of increasing the biocompatibility of the first siRNA conjugate in the target organ or tissue for delivery.
[0062] In general, the conjugated group comprises at least one pharmaceutically acceptable targeting group and an optional linker, and the siRNA group, the linker and the targeting group are connected in sequence. In some embodiments, the targeting group is 1-6. In some embodiments, the targeting group is 2-4. The siRNA group can be non-covalently or covalently conjugated to the conjugated group, for example, it can be covalently conjugated to the conjugated group. The conjugation site of the siRNA group and the conjugated group can be at the 3' end or 5' end of the sense strand in the siRNA group, or at the 5' end of the antisense strand, or in the internal sequence of the siRNA group. In some embodiments, the conjugation site of the siRNA group and the conjugated group is at the 3' end of the sense strand.
[0063] In some embodiments, the conjugate group can be connected to the phosphate group, 2'-hydroxyl group or base in the siRNA group. In some embodiments, the conjugate group can be connected to the 3'-hydroxyl group, in which case the nucleotides are connected by a 2'-5' phosphodiester bond. When the conjugate group is connected to the end of the siRNA group, the conjugate group is usually connected to the phosphate group of the nucleotide; when the conjugate group is connected to the internal sequence of the siRNA group, the conjugate group is usually connected to the ribose sugar ring or the base. For various connection methods, please refer to: Muthiah Manoharan et.al.siRNA conjugates carrying sequentially assembled trivalent N-acetylgalactosamine linked through nucleosides elicit robust gene silencing in vivo in hepatocytes.ACS Chemical biology, 2015, 10(5): 1181-7.
[0064] In some embodiments, the siRNA group and the conjugate group can be linked via acid-labile or reducible chemical bonds. In the acidic environment of endosomes, these chemical bonds can degrade, thereby freeing the siRNA group, for example, allowing the siRNA group to reform into the siRNA molecule. For non-degradable conjugation methods, the conjugate group can be attached to the sense strand of the siRNA group to minimize the effect of the conjugation on the inhibitory activity of the siRNA group.
[0065] The targeting group can be connected to the siRNA group via a suitable linker. Those skilled in the art can select a suitable linker based on the specific type of the targeting group. These linkers, the type of targeting group, and the mode of connection to the siRNA group can be found in the disclosure of WO2015006740A2, the entire contents of which are incorporated herein by reference.
[0066] In some embodiments, the targeting group can be a ligand commonly used in the field of siRNA administration, such as the various ligands described in WO2009082607A2, the entire disclosure of which is incorporated herein by reference.
[0067] In some embodiments, at least one or each of the targeting groups is selected from ligands that can bind to a surface receptor on a cell expressing the target gene.
[0068] In some embodiments, at least one or each of the targeting groups is selected from a ligand capable of binding to a receptor on the surface of a mammalian hepatocyte. In some embodiments, each of the targeting groups is independently a ligand that is affinity-bound to an asialoglycoprotein receptor on the surface of a mammalian hepatocyte. In some embodiments, each of the targeting groups is independently an asialoglycoprotein or sugar. In some embodiments, each of the targeting groups is independently selected from D-mannopyranose, L-mannopyranose, D-arabinose, D-xylofuranose, L-xylofuranose, D-glucose, L-glucose, D-galactose, L-galactose, α-D-mannofuranose, β-D-mannofuranose, α-D-mannopyranose, β-D-mannopyranose, α-D-glucose, β-D-glucose , α-D-glucofuranose, β-D-glucofuranose, α-D-fructofuranose, α-D-fructopyranose, α-D-galactopyranose, β-D-galactopyranose, α-D-galactofuranose, β-D-galactofuranose, glucosamine, sialic acid, galactosamine, N-acetylgalactosamine, N-trifluoroacetylgalactosamine, N-propionylgalactosamine, N-n-butyrylgalactosamine, N-isobutyrylgalactosamine, 2 -amino-3-O-[(R)-1-carboxyethyl]-2-deoxy-β-D-glucopyranose, 2-deoxy-2-methylamino-L-glucopyranose, 4,6-dideoxy-4-formamido-2,3-di-O-methyl-D-mannopyranose, 2-deoxy-2-sulfoamino-D-glucopyranose, N-glycolyl-α-neuraminic acid, 5-thio-β-D-glucopyranose, 2,3,4 - one of tri-O-acetyl-1-thio-6-O-trityl-α-D-glucopyranoside methyl ester, 4-thio-β-D-galactopyranose, 3,4,6,7-tetra-O-acetyl-2-deoxy-1,5-dithio-α-D-glucopyranoside heptoside ethyl ester, 2,5-anhydro-D-allosenitrile, ribose, D-ribose, D-4-thioribose, L-ribose, and L-4-thioribose. In some embodiments, at least one or each of the targeting groups is galactose or N-acetylgalactosamine.
[0069] In some embodiments, the linker in the siRNA conjugate has a structure as shown in formula (301):
[0070] Wherein, k is an integer from 1 to 3;
[0071] L A Having a structure including an amide bond as shown in formula (302), L B It has a structure containing N-acylpyrrolidine as shown in formula (303), containing a carbonyl group and an oxygen atom, L Cis a linking group based on hydroxymethylaminomethane, dihydroxymethylaminomethane or trishydroxymethylaminomethane;
[0072] Among them, n 302 ,q 302 and p 302 Each independently represents an integer from 2 to 6, optionally, n 302 ,q 302 and p 302 Each independently is 2 or 3; n 303 An integer between 4 and 16. Optionally, n 303 is an integer between 8 and 12, Indicates the site of covalent attachment of a group.
[0073] In the joint, each L A Each of the targeting groups is connected via an ether bond and connected via L C The oxygen atom of the hydroxyl group in the part is connected with L C Partially form ether bonds and connect; L B Through the carbonyl group in formula (303) and L C The nitrogen atom of the amino group in the moiety forms an amide bond to connect, and is connected to the siRNA group through the oxygen atom in formula (303) to form a phosphate bond or a phosphorothioate bond.
[0074] In some embodiments, the siRNA conjugate has a structure as shown in formula (305):
[0075] Wherein, Nu represents the first siRNA group, the second siRNA group or the third siRNA group.
[0076] In some embodiments, the linker in the siRNA conjugate has a structure represented by formula (306):
[0077] Among them, n 306 is an integer from 0 to 3, each p 306 are independently an integer from 1 to 6, Indicates the site of covalent attachment of a group; the linking group is connected to the targeting group through an ether bond formed by the oxygen atom marked by *; the linking group is connected to the siRNA group by at least one of the oxygen atoms marked by # forming a phosphate bond or a phosphorothioate bond, and the remaining oxygen atoms marked by # are connected to hydrogen atoms to form a hydroxyl group, or are connected to a C1-C3 alkyl group to form a C1-C3 alkoxy group;
[0078] In some embodiments, the siRNA conjugate has a structure as shown in formula (307):
[0079] Wherein, Nu represents the first siRNA group, the second siRNA group or the third siRNA group.
[0080] In some embodiments, the siRNA conjugate has a structure shown in formula (308):
[0081] in,
[0082] n1 is an integer selected from 1-3, n3 is an integer selected from 0-4;
[0083] Each m1, m2 or m3 is independently an integer selected from 2-10;
[0084] R 10 、R 11 、R 12 、R 13 、R 14 or R 15 are each independently H, or selected from the group consisting of: C1-C 10 Alkyl, C1-C 10 Halogenated alkyl and C1-C 10 alkoxy;
[0085] R3 has the structure shown in Formula A59:
[0086] wherein E1 is OH, SH or BH2, and Nu represents the first siRNA group, the second siRNA group or the third siRNA group;
[0087] R2 is a straight chain alkylene group having a length of 1 to 20 carbon atoms, wherein one or more carbon atoms are optionally replaced by any one or more selected from the group consisting of: C(O), NH, O, S, CH=N, S(O)2, C2-C 10 Alkenylene, C2-C 10 Alkynylidene, C6-C 10 Arylene, C3-C 18 Heterocyclylene and C5-C 10 Heteroarylene; and wherein R2 may optionally have any one or more substituents selected from the group consisting of: C1-C 10 Alkyl, C6-C 10 Aryl, C5-C 10 Heteroaryl, C1-C 10 Haloalkyl, -OC1-C 10 Alkyl, -OC1-C 10 Alkylphenyl, -C1-C 10Alkyl-OH, -OC1-C 10 Halogenated alkyl, -SC1-C 10 Alkyl, -SC1-C 10 Alkylphenyl, -C1-C 10 Alkyl-SH, -SC1-C 10 Haloalkyl, halogen substituent, -OH, -SH, -NH2, -C1-C 10 Alkyl-NH2, -N(C1-C 10 Alkyl)(C1-C 10 Alkyl), -NH(C1-C 10 Alkyl), -N(C1-C 10 Alkyl)(C1-C 10 Alkylphenyl), -NH(C1-C 10 alkylphenyl), cyano, nitro, -CO2H, -C(O)O(C1-C 10 Alkyl), -CON(C1-C 10 Alkyl)(C1-C 10 alkyl), -CONH(C1-C 10 alkyl), -CONH2, -NHC(O)(C1-C 10 Alkyl), -NHC(O)(phenyl), -N(C1-C 10 alkyl)C(O)(C1-C 10 Alkyl), -N(C1-C 10 alkyl)C(O)(phenyl), -C(O)C1-C 10 Alkyl, -C(O)C1-C 10 Alkylphenyl, -C(O)C1-C 10 Haloalkyl, -OC(O)C1-C 10 Alkyl, -SO2(C1-C 10 Alkyl), -SO2(phenyl), -SO2(C1-C 10 Halogenated alkyl), -SO2NH2, -SO2NH(C1-C 10 Alkyl), -SO2NH(phenyl), -NHSO2(C1-C 10 Alkyl), -NHSO2(phenyl) and -NHSO2(C1-C 10 haloalkyl);
[0088] Each L1 is independently a linear alkylene group having a length of 1 to 70 carbon atoms, wherein one or more carbon atoms are optionally replaced by any one or more selected from the group consisting of: C(O), NH, O, S, CH=N, S(O)2, C2-C 10 Alkenylene, C2-C 10 Alkynylidene, C6-C10 Arylene, C3-C 18 Heterocyclylene and C5-C 10 wherein L1 may optionally have any one or more substituents selected from the group consisting of: C1-C 10 Alkyl, C6-C 10 Aryl, C5-C 10 Heteroaryl, C1-C 10 Haloalkyl, -OC1-C 10 Alkyl, -OC1-C 10 Alkylphenyl, -C1-C 10 Alkyl-OH, -OC1-C 10 Halogenated alkyl, -SC1-C 10 Alkyl, -SC1-C 10 Alkylphenyl, -C1-C 10 Alkyl-SH, -SC1-C 10 Haloalkyl, halogen substituent, -OH, -SH, -NH2, -C1-C 10 Alkyl-NH2, -N(C1-C 10 Alkyl)(C1-C 10 Alkyl), -NH(C1-C 10 Alkyl), -N(C1-C 10 Alkyl)(C1-C 10 Alkylphenyl), -NH(C1-C 10 alkylphenyl), cyano, nitro, -CO2H, -C(O)O(C1-C 10 Alkyl), -CON(C1-C 10 Alkyl)(C1-C 10 alkyl), -CONH(C1-C 10 alkyl), -CONH2, -NHC(O)(C1-C 10 Alkyl), -NHC(O)(phenyl), -N(C1-C 10 alkyl)C(O)(C1-C 10 Alkyl), -N(C1-C 10 alkyl)C(O)(phenyl), -C(O)C1-C 10 Alkyl, -C(O)C1-C 10 Alkylphenyl, -C(O)C1-C 10 Haloalkyl, -OC(O)C1-C 10 Alkyl, -SO2(C1-C 10 Alkyl), -SO2(phenyl), -SO2(C1-C 10 Halogenated alkyl), -SO2NH2, -SO2NH(C1-C 10Alkyl), -SO2NH(phenyl), -NHSO2(C1-C 10 Alkyl), -NHSO2(phenyl) and -NHSO2(C1-C 10 haloalkyl);
[0089] represents the site of covalent attachment of a group;
[0090] M1 represents a targeting group, and its definition and selectable range are the same as above. In some embodiments, each M1 is independently selected from one of the ligands having affinity for the asialoglycoprotein receptor on the surface of mammalian liver cells.
[0091] The skilled artisan will appreciate that although L1 is defined as a linear alkyl group for convenience, it may not be a linear group or may be named differently, such as an amine or alkenyl group resulting from the above-mentioned substitutions and / or replacements. For the purposes of this disclosure, the length of L1 is the number of atoms in the chain connecting the two points of attachment. For this purpose, rings resulting from the replacement of carbon atoms of the linear alkylene group (e.g., heterocyclylene or heteroarylene) are counted as one atom.
[0092] When M1 is a ligand with affinity for the asialoglycoprotein receptor on the surface of mammalian liver cells, in some embodiments, n1 can be an integer from 1 to 3, and n3 can be an integer from 0 to 4, ensuring that the number of M1 ligands in the conjugate is at least 2. In some embodiments, n1 + n3 ≥ 2, which can result in the number of M1 ligands being at least 3, making it easier for the M1 ligand to bind to the asialoglycoprotein receptor on the liver surface, thereby promoting the conjugate to enter the cell via endocytosis. Experiments have shown that when the number of M1 ligands is greater than 3, the increased ease of binding of the M1 ligand to the asialoglycoprotein receptor on the liver surface is not significantly increased. Therefore, considering multiple factors such as ease of synthesis, structural / processing costs, and delivery efficiency, in some embodiments, n1 is an integer from 1 to 2, n3 is an integer from 0 to 1, and n1 + n3 = 2-3.
[0093] In some embodiments, when m1, m2 and m3 are independently selected from integers of 2-10, the spatial positions between multiple M1 ligands can be made suitable for the binding of M1 ligands to the asialoglycoprotein receptor on the liver surface. In order to make the conjugate provided by the present disclosure simpler, easier to synthesize and / or reduce costs, in some embodiments, m1, m2 and m3 are each independently an integer of 2-5. In some embodiments, m1=m2=m3.
[0094] Those skilled in the art will understand that when R 10 、R 11 、R 12 、R 13、R 14 and R 15 Each independently selected from H, C1-C 10 Alkyl, C1-C 10 Halogenated alkyl, and C1-C 10 In some embodiments, R 10 、R 11 、R 12 、R 13 、R 14 and R 15 Each is independently selected from H, methyl and ethyl. 10 、R 11 、R 12 、R 13 、R 14 and R 15 Both are H.
[0095] In some embodiments, R3 is a group represented by the structure of formula A59, wherein E1 is OH, SH or BH2. Based on the consideration of the availability of raw materials for preparation, in some embodiments, E1 is OH or SH.
[0096] In some embodiments, R2 is selected to achieve connection with N and A59 on the nitrogen-containing skeleton. In the context of this disclosure, "nitrogen-containing skeleton" refers to a skeleton having R 10 、R 11 、R 12 、R 13 、R 14 and R 15 The carbon atoms of R2 are connected to each other in a chain structure. Therefore, R2 can be any connecting group that can connect the A59 group to the N on the nitrogen-containing skeleton in an appropriate manner. In some embodiments, when the siRNA conjugate is prepared by a solid phase synthesis process, the R2 group needs to contain both a connection site connected to the N on the nitrogen-containing skeleton and a connection site connected to the P in R3. In some embodiments, the site in R2 that is connected to the N on the nitrogen-containing skeleton forms an amide bond with N, and the site that is connected to the P on R3 forms a phosphate bond with P. In some embodiments, the length of R2 is 4-15 atoms, or 6-10 atoms. In some embodiments, R2 is B5, B6, B5' or B6':
[0097] in, Indicates the site of covalent attachment of a group.
[0098] The value range of q2 can be an integer from 1 to 10. In some embodiments, q2 is an integer from 1 to 5.
[0099] L1 functions to connect the M1 ligand to the nitrogen-containing backbone, providing targeting functionality to the siRNA conjugate. In some embodiments, L1 is selected from a combination of one or more of the groups in formulae A1-A26. In some embodiments, L1 is selected from a combination of one or more of A1, A4, A5, A6, A8, A10, A11, and A13; in some embodiments, L1 is selected from a combination of at least two of A1, A4, A8, A10, and A11; in some embodiments, L1 is selected from a combination of at least two of A1, A8, and A10.
[0100] In some embodiments, L1 can be 3-25 atoms, 3-20 atoms, 4-15 atoms, or 5-12 atoms in length. In some embodiments, L1 is 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 55, or 60 atoms in length.
[0101] In some embodiments, j1 is an integer of 2-10, and in some embodiments, j1 is an integer of 3-5. In some embodiments, j2 is an integer of 2-10, and in some embodiments, j2 is an integer of 3-5. R' is a C1-C4 alkyl group, and in some embodiments, R' is one of methyl, ethyl, and isopropyl. Ra is one of A27, A28, A29, A30, and A31, and in some embodiments, Ra is A27 or A28. Rb is a C1-C5 alkyl group, and in some embodiments, Rb is one of methyl, ethyl, isopropyl, and butyl. In some embodiments, j1, j2, R', Ra, and Rb are each selected in formulas A1-A26 to achieve connection between the M1 ligand and the N on the nitrogen-containing skeleton, and to make the spatial position between the M1 ligands more suitable for binding of the M1 ligand to the liver surface asialoglycoprotein receptor.
[0102] In some embodiments, the siRNA conjugate has a structure represented by formula (403), (404), (405), (406), (407), (408), (409), (410), (411), (412), (413), (414), (415), (416), (417), (418), (419), (420), (421), or (422):
[0103] In some embodiments, P in Formula A59 can be linked to any possible position in the siRNA group, for example, P in Formula A59 can be linked to any nucleotide of the sense strand or antisense strand in the siRNA group; in some embodiments, P in Formula A59 is linked to any nucleotide of the sense strand. In some embodiments, P in Formula A59 is linked to the end of the sense strand or antisense strand; in some embodiments, P in Formula A59 is linked to the end of the sense strand. The end refers to the first 4 nucleotides of the sense strand or antisense strand from one end. In some embodiments, P in Formula A59 is linked to the end of the sense strand or antisense strand in the siRNA group; in some embodiments, P in Formula A59 is linked to the 3' end of the sense strand. When linked to the above-mentioned position of the sense strand, after the siRNA conjugate enters the cell, it can release a separate siRNA antisense strand when unwinding to regulate target gene expression.
[0104] The P in formula A59 can be connected to any possible position on the nucleotide in the siRNA group, for example, the 5' position of the nucleotide, the 2' position of the nucleotide, the 3' position of the nucleotide, or the base of the nucleotide. In some embodiments, the P in formula A59 can be connected to the 2' position, 3' position, or 5' position of the nucleotide in the siRNA group by forming a phosphodiester bond. In some embodiments, the P in formula A59 is connected to the oxygen atom formed after dehydrogenation of the 3' hydroxyl group of the nucleotide at the 3' end of the sense strand, or the P in formula A59 is connected to the nucleotide by replacing the hydrogen in the 2'-hydroxyl group of one nucleotide in the sense strand, or the P in formula A59 is connected to the nucleotide by replacing the hydrogen in the 5' hydroxyl group of the nucleotide at the 5' end of the sense strand.
[0105] It is well known to those skilled in the art that modified nucleotide groups can be introduced into the siRNA described in the present disclosure by using nucleoside monomers with corresponding modifications. Methods for preparing nucleoside monomers with corresponding modifications and methods for introducing modified nucleotide groups into siRNA are also well known to those skilled in the art. All modified nucleoside monomers are commercially available or can be prepared using known methods.
[0106] The siRNA conjugates disclosed herein can be prepared using any reasonable synthetic route. For example, for a conjugate molecule comprising a targeting group and an active reactive group that can react with a phosphoramidite to form a covalent bond, the active group in the conjugate molecule can be first protected with a protective agent and then attached to a solid support. Subsequently, a phosphoramidite solid-phase synthesis method is used to connect nucleoside monomers one by one in the 3' to 5' direction according to the nucleotide type and sequence of the siRNA sense and antisense strands. The connection of each nucleoside monomer includes four steps: deprotection, coupling, capping, and oxidation or sulfurization. The sense and antisense strands of the siRNA are separated and annealed to obtain the siRNA conjugates disclosed herein.
[0107] Furthermore, the preparation of siRNA conjugates can also be carried out with reference to the disclosures of existing literature. For example, WO2019010274A1 describes in Example 1 a method for sequentially connecting a linking group and a targeting ligand having a specific structure to siRNA through reaction. The entire contents are incorporated herein by reference. For another example, WO2015006740A2 describes in detail the preparation methods of various siRNA conjugates. For example, WO2014025805A1 describes the preparation method of the structure shown in formula (305), and Rajeev et al. describe the preparation method of the structure shown in formula (307) in ChemBioChem 2015, 16, 903-908. Chinese patent application CN110959011A also discloses in detail a method for preparing the siRNA conjugate shown in formula (308). The contents of the above-mentioned documents are incorporated herein by reference as a whole.
[0108] The above description of the siRNA conjugates is also applicable to the second siRNA and the third siRNA conjugates described below.
[0109] In the siRNA, pharmaceutical composition or siRNA conjugate disclosed herein, the siRNA or siRNA conjugate may exist in a salted form or an unsalted form. In the siRNA, pharmaceutical composition or siRNA conjugate disclosed herein, the siRNA or siRNA conjugate may exist in the form of a partial or complete water-soluble salt, and the water-soluble salt may be an amine salt or an alkali metal salt thereof. In some embodiments, the alkali metal salt may be a potassium salt or a sodium salt. In some embodiments, the amine salt may be an ammonium salt, a methylamine salt or a triethylamine salt. In the first siRNA and / or the first siRNA conjugate, the second siRNA and / or the second siRNA conjugate, the third siRNA and / or the third siRNA conjugate described above and below, each adjacent nucleotide is connected by a phosphodiester bond or a thiophosphate diester bond, and the non-bridging oxygen atom or sulfur atom in the phosphodiester bond or the thiophosphate diester bond carries a negative charge, which may exist in the form of a hydroxyl group or a sulfhydryl group, and the hydrogen ion in the hydroxyl group or the sulfhydryl group may also be partially or completely replaced by a cation. The cation may be any cation, such as a metal cation, an ammonium ion NH4 + , one of the organic ammonium cations. The organic ammonium cation can be a cation formed by methylamine, a cation formed by triethylamine, or a quaternary ammonium cation. In order to improve solubility, in one embodiment, the cation is selected from one or more of an alkali metal ion, an ammonium cation formed by a tertiary amine, and a quaternary ammonium cation. The alkali metal ion can be K + and / or Na + The cation formed by the tertiary amine can be an ammonium ion formed by triethylamine and / or an ammonium ion formed by N,N-diisopropylethylamine. Therefore, the siRNA or siRNA conjugate described in the present disclosure can exist at least partially in the form of a salt. In one embodiment, the non-bridging oxygen atom or sulfur atom in the phosphodiester bond or phosphorothioate diester bond is at least partially bound to a sodium ion, that is, the siRNA or siRNA conjugate exists in the form of a sodium salt or a partial sodium salt.
[0110] In some embodiments, the first RNAi agent contains 2-4 first siRNAs and / or first siRNA conjugates, wherein the content of each first siRNA and / or first siRNA conjugate is equal or unequal. In some embodiments, the first RNAi agent contains 2 first siRNAs and / or first siRNA conjugates, and the ratio between the two can be 0.1-10, such as 0.4-5.
[0111] In some embodiments, for ease of preparation, the first RNAi agent contains only one first siRNA or first siRNA conjugate. In some embodiments, for better delivery effect, the first RNAi agent contains only one first siRNA conjugate.
[0112] The second RNAi agent in the pharmaceutical composition of the present disclosure
[0113] In the context of the present disclosure, the second RNAi agent comprises one or more second siRNAs and / or one or more second siRNA conjugates, each second siRNA being independently an siRNA capable of inhibiting PCSK9 mRNA, and each second siRNA conjugate comprising an siRNA group formed by one second siRNA and a conjugated group conjugated thereto.
[0114] The siRNA capable of inhibiting PCSK9 mRNA can be any siRNA capable of inhibiting PCSK9 mRNA. In some embodiments, each second siRNA comprises a sense strand and an antisense strand, and each nucleotide in the sense strand and the antisense strand is independently a modified or unmodified nucleotide; wherein the sense strand is 18-23 nucleotides in length, and the antisense strand is 18-26 nucleotides in length, and the sense strand and the antisense strand are substantially reverse complementary or completely reverse complementary. The second siRNA comprises at least one siRNA, and the sense strand of the second siRNA is identical to the nucleotide sequence shown in SEQ ID NO: 3 for at least 15 consecutive nucleotides:
[0115] 5'-UUCUAGACCUGUUUUGCUUUUGUAACUUGA-3' (SEQ ID NO: 3).
[0116] In some embodiments, the sense strand of the siRNA is identical to the nucleotide sequence of SEQ ID NO: 3 for at least 15, 16, 17, 18, or 19 consecutive nucleotides. In some embodiments, in the 5'-3' direction, the sense strand comprises a nucleotide sequence that is identical to nucleotides 9-27 of the nucleotide sequence of SEQ ID NO: 3.
[0117] The lengths of the sense strand and the antisense strand in the second siRNA may be the same or different. In some embodiments, the length ratio of the sense strand and the antisense strand of the second siRNA may be 19 / 19, 19 / 20, 19 / 21, 19 / 22, 19 / 23, 19 / 24, 19 / 25, 19 / 26, 20 / 20, 20 / 21, 20 / 22, 20 / 23, 20 / 24 In some embodiments, the length ratio of the second siRNA sense strand to the antisense strand is 19 / 21, 21 / 23 or 23 / 25.
[0118] In some embodiments, in the second siRNA, some nucleotides in the sense strand and the antisense strand are modified nucleotides, and some nucleotides are unmodified nucleotides. In some embodiments, in the second siRNA, all nucleotides in the sense strand and the antisense strand are modified nucleotides; from the 5' end to the 3' end, the 7th to 9th nucleotides of the sense strand are 2'-fluoro-modified nucleotides, and from the 5' end to the 3' end, the 2nd, 6th, 14th, and 16th nucleotides of the antisense strand are 2'-fluoro-modified nucleotides, and the other nucleotides in the antisense strand are each independently one of non-fluoro-modified nucleotides.
[0119] In some embodiments, the second siRNA can be, for example, any of the siRNAs listed in Table 2. siRNA conjugates comprising these siRNAs or siRNA groups formed from these siRNAs exhibit high PCSK9 mRNA inhibitory activity. To achieve a better inhibitory effect, in some embodiments, the second siRNA has a sequence as shown in siPCSKd1-M1S.
[0120] Table 2. Sequences of the second siRNA
[0121] Wherein, the capital letters C, G, U, and A represent the base composition of the nucleotide; the lowercase letter m indicates that the nucleotide adjacent to the left of the letter m is a methoxy-modified nucleotide; the lowercase letter f indicates that the nucleotide adjacent to the left of the letter f is a fluorinated modified nucleotide; the lowercase letter s indicates that the two nucleotides to the left of the letter s are connected by a phosphorothioate group; P1 indicates that the nucleotide adjacent to the right of P1 is a 5'-phosphate nucleotide or a 5'-phosphate analog modified nucleotide. In some embodiments, P1 is VP, Ps, or P, which represents a specific modification, wherein the letter combination VP indicates that the nucleotide adjacent to the right of the letter combination VP is a vinyl phosphate (5'-(E)-vinylphosphonate, E-VP) modified nucleotide, the letter combination Ps indicates that the nucleotide adjacent to the right of the letter combination Ps is a phosphorothioate modified nucleotide, and the capital letter P indicates that the nucleotide adjacent to the right of the letter P is a 5'-phosphate nucleotide. In addition, each U in the sequence listed in Table 2 above can be arbitrarily replaced by T without significantly affecting the activity or off-target effects of the siRNA.
[0122] In some embodiments, the conjugated group in each of the second siRNA conjugates comprises a linker and a pharmaceutically acceptable targeting group and / or a delivery auxiliary group, and the second siRNA group, the linker and the targeting group or the delivery auxiliary group are covalently or non-covalently linked in sequence, and the definition and selection of the targeting group are the same as those of the first siRNA conjugate. In some embodiments, the second siRNA conjugate has a structure as shown in formula (403).
[0123] In some embodiments, the second RNAi agent contains 2-4 second siRNAs and / or second siRNA conjugates, wherein the content of each second siRNA and / or second siRNA conjugate is equal or unequal. In some embodiments, the second RNAi agent contains 2 second siRNAs and / or second siRNA conjugates, and the ratio between the two can be 0.1-10, such as 0.4-5.
[0124] In some embodiments, for ease of preparation, the second RNAi agent contains only one second siRNA or second siRNA conjugate. In some embodiments, for better delivery effect, the second RNAi agent contains only one second siRNA conjugate.
[0125] In some embodiments, in the pharmaceutical composition provided herein, the first RNAi agent contains only one first siRNA conjugate and / or the second RNAi agent contains only one second siRNA conjugate; the sense strand of the first siRNA is substantially reverse complementary or completely reverse complementary to the antisense strand, and the sense strand of the first siRNA is at least 15 consecutive nucleotides identical to the nucleotide sequence as shown in SEQ ID NO: 1, or the sense strand of the second siRNA is at least 15 consecutive nucleotides identical to the nucleotide sequence as shown in SEQ ID NO: 2; the sense strand of the second siRNA is substantially reverse complementary or completely reverse complementary to the antisense strand, and the sense strand is at least 15 consecutive nucleotides identical to the nucleotide sequence as shown in SEQ ID NO: 3;
[0126] 5'-UGGCCUCCCAAUAAAGCUGGACAAGAAGCU-3' (SEQ ID NO: 1);
[0127] 5'-UGCUUAAAAGGGACAGUAUUCUCAGUGCUC-3' (SEQ ID NO: 2);
[0128] 5'-UUCUAGACCUGUUUUGCUUUUGUAACUUGA-3' (SEQ ID NO: 3).
[0129] The third RNAi agent in the pharmaceutical composition of the present disclosure
[0130] In some embodiments, the pharmaceutical composition of the present disclosure may further comprise a third RNAi agent, comprising one or more third siRNAs and / or one or more third siRNA conjugates, each third siRNA being independently an siRNA capable of inhibiting ANGPTL3 mRNA, and each third siRNA conjugate comprising an siRNA group formed from one of the third siRNAs and a conjugated group conjugated thereto. In some embodiments, the third RNAi agent and the first and / or second RNAi agent exhibit a synergistic effect, further enhancing the therapeutic and / or preventive effect of the pharmaceutical composition of the present disclosure on diseases and / or symptoms associated with hyperlipidemia.
[0131] The siRNA capable of inhibiting ANGPTL3 mRNA can be any siRNA capable of inhibiting ANGPTL3 mRNA. In some embodiments, each third siRNA comprises a sense strand and an antisense strand, and each nucleotide in the sense strand and the antisense strand is independently a modified or unmodified nucleotide; wherein the sense strand is 18-23 nucleotides in length, and the antisense strand is 18-26 nucleotides in length, and the sense strand and the antisense strand are substantially reverse complementary or completely reverse complementary. The third siRNA includes at least one siRNA, and the sense strand of the third siRNA is identical to the nucleotide sequence shown in SEQ ID NO: 4 for at least 15 consecutive nucleotides:
[0132] 5'-AGCCAAAAUCAAGAUUUGCUAUGUUAGACG-3' (SEQ ID NO: 4).
[0133] In some embodiments, the sense strand of the siRNA is identical to the nucleotide sequence of SEQ ID NO: 4 for at least 15, 16, 17, 18, or 19 consecutive nucleotides. In some embodiments, in the 5'-3' direction, the sense strand comprises a nucleotide sequence that is identical to nucleotides 9-27 of the nucleotide sequence of SEQ ID NO: 3, or a nucleotide sequence that differs from nucleotides 9-27 of the nucleotide sequence of SEQ ID NO: 3 by no more than one nucleotide.
[0134] The lengths of the sense strand and the antisense strand in the third siRNA may be the same or different. In some embodiments, the length ratio of the sense strand and the antisense strand of the third siRNA may be 19 / 19, 19 / 20, 19 / 21, 19 / 22, 19 / 23, 19 / 24, 19 / 25, 19 / 26, 20 / 20, 20 / 21, 20 / 22, 20 / 23, 20 / 24 In some embodiments, the length ratio of the second siRNA sense strand to the antisense strand is 19 / 21, 21 / 23 or 23 / 25.
[0135] In some embodiments, in the third siRNA, some nucleotides in the sense strand and the antisense strand are modified nucleotides, and some nucleotides are unmodified nucleotides. In some embodiments, in the third siRNA, all nucleotides in the sense strand and the antisense strand are modified nucleotides; from the 5' end to the 3' end, the 7th to 9th nucleotides of the sense strand are 2'-fluoro-modified nucleotides, and from the 5' end to the 3' end, the 2nd, 6th, 14th, and 16th nucleotides of the antisense strand are 2'-fluoro-modified nucleotides, and the other nucleotides in the antisense strand are each independently one of non-fluoro-modified nucleotides.
[0136] In some embodiments, the third siRNA can be, for example, any of the siRNAs listed in Table 3. siRNA conjugates comprising or consisting of these siRNAs exhibit high ANGPTL3 mRNA inhibitory activity. To achieve a better inhibitory effect, in some embodiments, the third siRNA has a sequence such as siANGa1-M1S or siANGa1-M2S.
[0137] Table 3 Sequence of the third siRNA
[0138] Wherein, the capital letters C, G, U, and A represent the base composition of the nucleotide; the lowercase letter m indicates that the nucleotide adjacent to the left of the letter m is a methoxy-modified nucleotide; the lowercase letter f indicates that the nucleotide adjacent to the left of the letter f is a fluorinated modified nucleotide; the underlined capital letter S indicates that the nucleotide adjacent to the left of the letter S is a stabilizing modified nucleotide; the lowercase letter s indicates that the two nucleotides to the left of the letter s are linked by a phosphorothioate group; P1 indicates that the nucleotide adjacent to the right of P1 is a 5'-phosphate nucleotide or a 5'-phosphate analog modified nucleotide. In some embodiments, S represents a specific stabilizing modification such as moe, wherein the underlined letter combination moe indicates that the nucleotide adjacent to the left of the letter combination moe is a nucleotide with a 2'-O-methoxyethyl modification. In some embodiments, P1 represents a specific modification of VP, Ps, or P, wherein the letter combination VP indicates that the nucleotide adjacent to the right of the letter combination VP is a vinyl phosphate (5'-(E)-vinylphosphonate, E-VP)-modified nucleotide, the letter combination Ps indicates that the nucleotide adjacent to the right of the letter combination Ps is a phosphorothioate-modified nucleotide, and the capital letter P indicates that the nucleotide adjacent to the right of the letter P is a 5'-phosphate nucleotide. In addition, each U in the sequence listed in Table 3 above can be arbitrarily replaced by T without significantly affecting the activity or off-target effects of the siRNA.
[0139] In some embodiments, the conjugated group in each of the third siRNA conjugates comprises a linker and a pharmaceutically acceptable targeting group and / or a delivery auxiliary group, and the third siRNA group, the linker and the targeting group or the delivery auxiliary group are covalently or non-covalently linked in sequence, and the definition and selection of the targeting group are the same as those of the first siRNA conjugate. In some embodiments, the third siRNA conjugate has a structure as shown in formula (403).
[0140] In some embodiments, the third RNAi agent contains 2-4 third siRNAs and / or third siRNA conjugates, wherein the content of each third siRNA and / or third siRNA conjugate is equal or unequal. In some embodiments, the second RNAi agent contains 2 third siRNAs and / or third siRNA conjugates, and the ratio between the two can be 0.1-10, such as 0.4-5.
[0141] In some embodiments, for ease of preparation, the third RNAi agent contains only one third siRNA or third siRNA conjugate. In some embodiments, for better delivery effect, the third RNAi agent contains only one third siRNA conjugate.
[0142] Solvents, pharmaceutically acceptable carriers and excipients
[0143] In some embodiments, for ease of use, the first RNAi agent, the second RNAi agent, and the third RNAi agent are present in the form of various RNAi preparations commonly used in the art.
[0144] In some embodiments, at least one or each of the first RNAi agent, the second RNAi agent, and the third RNAi agent further comprises one or more of a solvent, a pharmaceutically acceptable carrier, and an excipient. The following definitions and selection ranges of solvents, pharmaceutically acceptable carriers, and excipients apply to the first RNAi agent, the second RNAi agent, and the third RNAi agent.
[0145] In some embodiments, the RNAi formulation can be a liquid formulation, such as an injection. The liquid formulation can be an injection for subcutaneous injection, an injection for intramuscular injection, or an injection for intravenous injection. In some embodiments, the solvent can include various solvents such as water, deionized water, ethanol, a pH buffer solution, and other common solvents. The pH buffer solution can be a tris-hydrochloride buffer solution with a pH value of 7.5-8.5 and / or a phosphate buffer solution with a pH value of 5.5-8.5, for example, a phosphate buffer solution with a pH value of 5.5-8.5.
[0146] The amount of the solvent is adjusted according to the desired injection concentration. Based on the siRNA or siRNA group, the solution dissolves the siRNA or is formulated into a solution with a concentration of 0.01 mg / mL-200 mg / mL siRNA, 20 mg / mL-200 mg / mL, 50 mg / mL-100 mg / mL, 0.01 mg / mL-5 mg / mL siRNA, 0.1 mg / mL-5 mg / mL, or 0.5 mg / mL-3 mg / mL. The amount of the solvent can be easily determined by those skilled in the art based on the desired concentration.
[0147] In order to obtain a better inhibitory effect, in some embodiments, the first RNAi agent, the second RNAi agent and the third RNAi agent are all in the form of a preparation for subcutaneous injection.
[0148] In some embodiments, in order to facilitate transportation and / or storage, all siRNAs and siRNA conjugates in the first RNAi agent and / or the second RNAi agent and / or the third RNAi agent are in the form of powder, for example, in the form of a lyophilized powder injection. When the drug is administered, the lyophilized powder injection is mixed with a solvent to prepare a liquid preparation.
[0149] In some embodiments, the first RNAi agent, the second RNAi agent, and the third RNAi agent can also be a spray formulation for administration to the lungs by spray or to other organs and tissues (such as the liver) through the lungs, an inhalation formulation for inhalation through the oropharynx, or a pharmaceutical preparation for nasal administration, etc. Therefore, the first component contains at least one of siRNA and siRNA conjugate and a pharmaceutically acceptable carrier and / or excipient. The types and contents of the carriers and / or excipients in the injection for subcutaneous injection, the injection for intramuscular injection, the injection for intravenous injection, the spray formulation for administration to the lungs by spray or to other organs and tissues (such as the liver) through the lungs, an inhalation formulation for inhalation through the oropharynx, or a pharmaceutical preparation for nasal administration, etc., are well known to those skilled in the art.
[0150] The pharmaceutically acceptable carrier may be a carrier conventionally used in the field of siRNA administration, such as, but not limited to, magnetic nanoparticles (e.g., nanoparticles based on Fe3O4 or Fe2O3), carbon nanotubes, mesoporous silicon, calcium phosphate nanoparticles, polyethylenimine (PEI), polyamidoamine (PAMAM) dendrimer, poly(L-lysine, PLL), chitosan, 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), poly (D&L-lactic / glycolic acid) copolymer (PLGA), poly(2-aminoethyl ethylene phosphate), poly(L-lysine, PLL ... phosphate), PPEEA) and poly (methacrylate-N, N-dimethylaminoethyl ester) (poly (2-dimethylaminoethyl methacrylate), PDMAEMA) and one or more of their derivatives.
[0151] The amounts of siRNA, siRNA conjugate, and pharmaceutically acceptable carrier in the first component are conventional amounts known to those skilled in the art. In some embodiments, the weight ratio of the total amount of siRNA and siRNA conjugate to the pharmaceutically acceptable carrier, calculated as siRNA or siRNA groups, can be 1:1-1:1000, 1:1-1:500, 1:1-1:200, 1:1-1:100, or 1:1-1:50.
[0152] The pharmaceutically acceptable excipients are one or more of various ingredients conventionally used in the art, such as diluents, binders, disintegrants, lubricants, capsules, protective agents, osmotic agents, etc., but do not include the aforementioned solvents.
[0153] The protective agent can be at least one of inositol, sorbitol, sucrose, trehalose, mannose, maltose, lactose and glucose. The content of the protective agent can be 0.01-30% of the total weight of the first component.
[0154] The osmotic pressure regulator can be sodium chloride and / or potassium chloride. The content of the osmotic pressure regulator makes the osmotic pressure of the injection solution be 200-700 milliosmoles / kilogram (mOsm / kg). According to the desired osmotic pressure, those skilled in the art can easily determine the content of the osmotic pressure regulator. In some embodiments, the dosage of the first component during administration can be adjusted due to different administration methods.
[0155] In some embodiments, the first siRNA, the second siRNA and / or the third siRNA are present in the form of liposomes. In some embodiments, the pharmaceutically acceptable carrier used in the liposomes comprises an amine-containing transfection compound (hereinafter also referred to as an organic amine), a helper lipid and / or a pegylated lipid. Wherein, the organic amine, the helper lipid and the pegylated lipid can be selected from one or more of the amine-containing transfection compound or its pharmaceutically acceptable salt or derivative, the helper lipid and the pegylated lipid described in Chinese patent application CN103380113A (incorporated herein by reference in its entirety).
[0156] In some embodiments, the organic amine may be a compound described in Chinese patent application CN103380113A as shown in formula (201) or a pharmaceutically acceptable salt thereof:
[0157] in:
[0158] X 101 and X 102are each independently O, S, NA or CA, wherein A is hydrogen or C1-C 20 hydrocarbon chain;
[0159] Y 101 and Z 101 Each independently is C=O, C=S, S=O, CH-OH or SO2;
[0160] R 101 、R 102 、R 103 、R 104 、R 105 、R 106 and R 107 are each independently hydrogen, a cyclic or acyclic, substituted or unsubstituted, branched or straight-chain aliphatic group, a cyclic or acyclic, substituted or unsubstituted, branched or straight-chain heteroaliphatic group, a substituted or unsubstituted, branched or straight-chain acyl group, a substituted or unsubstituted, branched or straight-chain aryl group, a substituted or unsubstituted, branched or straight-chain heteroaryl group;
[0161] x is an integer from 1 to 10;
[0162] n is an integer from 1 to 3, m is an integer from 0 to 20, and p is 0 or 1; wherein, if m=p=0, then R 102 It is hydrogen;
[0163] And, if at least one of n or m is 2, then R 103 and the nitrogen in formula (201) to form a structure as shown in formula (202) or formula (203):
[0164] wherein g, e, and f are each independently an integer of 1 to 6, "HCC" represents a hydrocarbon chain, and each *N represents a nitrogen atom in formula (201).
[0165] In some embodiments, R 103 is a polyamine. In other embodiments, R 103 In some embodiments, R in formula (201) 101 and R 102 Each of is independently an optionally substituted or unsubstituted, branched or straight chain alkyl or alkenyl group having 3 to about 20 carbon atoms, such as 8 to about 18 carbon atoms, and 0 to 4 double bonds, such as 0 to 2 double bonds.
[0166] In some embodiments, if each of n and m independently has a value of 1 or 3, then R 103 It can be any one of the following formulas (204) to (213):
[0167] Wherein, in formula (204) to formula (213), g, e and f are each independently an integer of 1 to 6, each "HCC" represents a hydrocarbon chain, and each * indicates R 103 Possible points of attachment to the nitrogen atom in formula (201), wherein each H at any * position can be replaced to achieve attachment to the nitrogen atom in formula (201).
[0168] Those skilled in the art can obtain the compound represented by formula (201) by any reasonable method. In some embodiments, the compound represented by formula (201) can be prepared according to the description in Chinese patent application CN103380113A.
[0169] In some embodiments, the organic amine is an organic amine represented by formula (214) and / or an organic amine represented by formula (215):
[0170] The helper lipid is cholesterol, a cholesterol analogue and / or a cholesterol derivative;
[0171] The PEGylated lipid is 1,2-dipalmitoyl-sn-glycero-3-phosphatidylethanolamine-N-[methoxy(polyethylene glycol)]-2000.
[0172] In some embodiments, in the pharmaceutical composition, the molar ratio of the organic amine, the auxiliary lipid and the pegylated lipid is (19.7-80):(19.7-80):(0.3-50), for example, it can be (50-70):(20-40):(3-20).
[0173] In some embodiments, the particles of siRNA liposomes formed by the first siRNA and / or the second siRNA and / or the third siRNA and the above-mentioned amine-containing transfection reagent have an average diameter of about 30 nm to about 200 nm, typically about 40 nm to about 135 nm, more typically, the average diameter of the liposome particles is about 50 nm to about 120 nm, about 50 nm to about 100 nm, about 60 nm to about 90 nm or about 70 nm to about 90 nm, for example, the average diameter of the liposome particles is about 30, 40, 50, 60, 70, 75, 80, 85, 90, 100, 110, 120, 130, 140, 150 or 160 nm.
[0174] In some embodiments, in the siRNA liposomes formed by the first siRNA and / or the second siRNA and / or the third siRNA in the pharmaceutical composition of the present disclosure and the above-mentioned amine-containing transfection reagent, the weight ratio (weight / weight ratio) of total siRNA to total lipids (e.g., organic amines, helper lipids and / or pegylated lipids) is in the range of from about 1:1 to about 1:50, from about 1:1 to about 1:30, from about 1:3 to about 1:20, from about 1:4 to about 1:18, from about 1:5 to about 1:17, from about 1:5 to about 1:15, from about 1:5 to about 1:12, from about 1:6 to about 1:12, or from about 1:6 to about 1:10, for example, can be about 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:11, 1:12, 1:13, 1:14, 1:15, 1:16, 1:17 or 1:18.
[0175] In some embodiments, the siRNA liposomes can be prepared according to various known methods, except that the siRNA is used to replace the existing siRNA; in some embodiments, the siRNA liposomes can be prepared according to the following method:
[0176] The organic amine, the helper lipid, and the PEGylated lipid are suspended in alcohol in the above molar ratio and mixed to obtain a lipid solution; the amount of alcohol used is such that the total mass concentration of the obtained lipid solution is 2-25 mg / mL, for example, 8-18 mg / mL. The alcohol is selected from pharmaceutically acceptable alcohols, such as alcohols that are liquid at around room temperature, for example, one or more of ethanol, propylene glycol, benzyl alcohol, glycerol, polyethylene glycol 200, polyethylene glycol 300, and polyethylene glycol 400, for example, ethanol.
[0177] The siRNA is dissolved in a buffered saline solution to obtain an siRNA aqueous solution. The concentration of the buffered saline solution is 0.05-0.5 M, for example, 0.1-0.2 M. The pH of the buffered saline solution is adjusted to 4.0-5.5, for example, 5.0-5.2. The amount of buffered saline solution used is such that the concentration of the siRNA does not exceed 0.6 mg / mL, for example, 0.2-0.4 mg / mL. The buffer salt is selected from one or more soluble acetates and soluble citrates, for example, sodium acetate and / or potassium acetate.
[0178] The lipid solution and the siRNA aqueous solution are mixed, and the resulting mixture is incubated at 40-60°C for at least 2 minutes, for example, 5-30 minutes, to obtain an incubated liposome formulation. The volume ratio of the lipid solution to the siRNA aqueous solution is 1:(2-5), for example, 1:4.
[0179] The incubated liposomes are concentrated or diluted, impurities are removed, and sterilized to obtain the siRNA-containing liposomes, whose physicochemical parameters are pH 6.5-8, encapsulation efficiency not less than 80%, particle size 40-200 nm, polydispersity index not higher than 0.30, and osmotic pressure 250-400 mOsm / kg; for example, the physicochemical parameters can be pH 7.2-7.6, encapsulation efficiency not less than 90%, particle size 60-100 nm, polydispersity index not higher than 0.20, and osmotic pressure 300-400 mOsm / kg.
[0180] Concentration or dilution can be performed before, after, or simultaneously with impurity removal. Impurity removal can be performed using various existing methods, such as ultrafiltration at 100K Da using a tangential flow system or a hollow fiber column, with the ultrafiltration exchange solution being phosphate buffered saline (PBS) at pH 7.4. Sterilization can be performed using various existing methods, such as filtration sterilization using a 0.22 μm filter.
[0181] In some embodiments, the pharmaceutical composition contains only the first RNAi agent and the second RNAi agent, wherein the first RNAi agent contains only one first siRNA conjugate or the second RNAi agent contains only one second siRNA conjugate. Alternatively, the first RNAi agent contains only one first siRNA conjugate, and the second RNAi agent contains only one second siRNA conjugate.
[0182] In some embodiments, the first RNAi agent and the second RNAi agent are present in separate preparations for subcutaneous injection, that is, the first RNAi agent and the second RNAi agent are stored separately and can be used separately. In some embodiments, the first RNAi agent and the second RNAi agent are mixed uniformly.
[0183] In some embodiments, the pharmaceutical composition contains a first RNAi agent, a second RNAi agent, and a third RNAi agent, wherein the first RNAi agent contains only one first siRNA conjugate, or the second RNAi agent contains only one second siRNA conjugate, or the third RNAi agent contains only one third siRNA conjugate. In some embodiments, the first RNAi agent contains only one first siRNA conjugate, and the second RNAi agent contains only one second siRNA conjugate, and the third RNAi agent contains only one third siRNA conjugate. In some embodiments, the first RNAi agent, the second RNAi agent, and the third RNAi agent are all present separately, in some embodiments, one of the first RNAi agent or the second RNAi agent and the third RNAi agent are present in the form of a uniformly mixed preparation for subcutaneous injection, and in some embodiments, the first RNAi agent, the second RNAi agent, and the third RNAi agent are present in the form of a uniformly mixed preparation for subcutaneous injection.
[0184] Reagent test kit
[0185] The pharmaceutical compositions provided herein can be stored in a kit. In some embodiments, the kit described herein can provide the first RNAi agent, the second RNAi agent, and the third RNAi agent in the pharmaceutical compositions provided herein in one or more containers. In some embodiments, in order to more conveniently use the pharmaceutical compositions of the present disclosure, the first RNAi agent and the second RNAi agent are stored separately in the kit. In some embodiments, the kit comprises a container for providing the first RNAi agent and a container for providing the second RNAi agent, and optionally, further comprises a container for providing the third component. In some embodiments, the kit may further comprise other ingredients, such as stabilizers or preservatives.
[0186] Application of the pharmaceutical composition disclosed herein
[0187] In another aspect, the present disclosure further discloses the use of the pharmaceutical composition of the present disclosure in the preparation of a medicament for treating and / or preventing diseases or symptoms associated with hyperlipidemia, wherein the diseases or symptoms associated with hyperlipidemia are selected from one or more of hypercholesterolemia, hypertriglyceridemia, and familial hypercholesterolemia.
[0188] In some embodiments, the first RNAi agent and the second RNAi agent in the pharmaceutical composition exist as two separate preparations during the preparation of the drug. In some embodiments, the first RNAi agent and the second RNAi agent in the pharmaceutical composition exist as one preparation during the preparation of the drug.
[0189] Method for treating and / or preventing diseases associated with hyperlipidemia
[0190] In another aspect, the present disclosure further provides a method for treating and / or preventing a disease associated with hyperlipidemia, the method comprising administering to a subject in need thereof an effective amount of a first RNAi agent and a second RNAi agent, wherein the first RNAi agent comprises one or more first siRNAs and / or one or more first siRNA conjugates, each first siRNA being independently an siRNA capable of inhibiting APOC3 mRNA, and each first siRNA conjugate comprising an siRNA group formed by one of the first siRNAs and a conjugated group conjugated thereto;
[0191] The second RNAi agent comprises one or more second siRNAs and / or one or more second siRNA conjugates, each second siRNA is independently an siRNA capable of inhibiting PCSK9 mRNA, and each second siRNA conjugate comprises an siRNA group formed by one second siRNA species and a conjugated group conjugated thereto;
[0192] The weight ratio of the first RNAi agent and the second RNAi agent administered to the subject is 10:1-1:10, based on the total amount of siRNA and siRNA groups contained in each of the first RNAi agent and the second RNAi agent.
[0193] Wherein, the diseases or symptoms related to hyperlipidemia are selected from one or more of hypercholesterolemia, hypertriglyceridemia and familial hypercholesterolemia.
[0194] The "effective amount" refers to a dose that can reduce the TC or LDL-c value in a subject by at least 5%, 10% or 20% compared to before administration.
[0195] In some embodiments, based on the total amount of siRNA and siRNA groups contained in each of the first and second RNAi agents, the weight ratio of the first RNAi agent and the second RNAi agent administered to the subject is 100: 1-1: 100, for example, 100: 1, 50: 1, 25: 1, 15: 1, 10: 1, 5: 1, 4: 1, 3: 1, 2: 1, 1: 1, 1: 100, 1: 50, 1: 25, 1: 15, 1: 10, 1: 5, 1: 3, 1: 4, 1: 2. In some embodiments, preferably, the weight ratio of the first RNAi agent and the second RNAi agent administered to the subject is 10: 1-1: 10, 5: 1-1: 5, or 2: 1-1: 5. In some embodiments, in order to obtain a better therapeutic / preventive effect, the weight of the second RNAi agent administered to the subject is not less than the weight of the first RNAi agent, and the weight ratio of the first RNAi agent to the second RNAi agent administered to the subject can be 1:1-1:10, 1:1-1:5 or 1:1-1:3.
[0196] In some embodiments, based on the total amount of siRNA and siRNA groups contained in each of the first RNAi agent and the second RNAi agent, the dose of the first RNAi agent administered to the subject each time is 0.5 mg / Kg-10 mg / Kg of the subject's body weight, for example, 0.5 mg / Kg-5 mg / Kg of the subject's body weight, 0.5 mg / Kg-3 mg / Kg of the subject's body weight, 1 mg / Kg-3 mg / Kg of the subject's body weight, or 1 mg / Kg-5 mg / Kg of the subject's body weight. The dose of the second RNAi agent administered to the subject each time is 0.5 mg / Kg-10 mg / Kg of the subject's body weight, for example, 0.5 mg / Kg-9 mg / Kg of the subject's body weight, 3 mg / Kg-10 mg / Kg of the subject's body weight, 1 mg / Kg-9 mg / Kg of the subject's body weight, 3 mg / Kg-9 mg / Kg of the subject's body weight, 1 mg / Kg-6 mg / Kg of the subject's body weight, or 3 mg / Kg-6 mg / Kg of the subject's body weight.
[0197] In some embodiments, the dose of the first RNAi agent administered to the subject each time is a fixed dose of 1 mg-1000 mg, for example, 1 mg-800 mg, 1 mg-600 mg, 1 mg-500 mg, 1 mg-300 mg, 1 mg-250 mg, or 1 mg-100 mg, based on the total amount of siRNA and siRNA groups contained in the first RNAi agent. In some embodiments, the dose of the first RNAi agent administered to the subject is 5 mg-500 mg.
[0198] In some embodiments, the dose of the second RNAi agent administered to the subject each time is a fixed dose of 1 mg-1000 mg, for example, 1 mg-800 mg, 1 mg-600 mg, 1 mg-500 mg, 1 mg-300 mg, 1 mg-250 mg, or 1 mg-100 mg, based on the total amount of siRNA and siRNA groups contained in the second RNAi agent. In some embodiments, the dose of the second RNAi agent administered to the subject is 5 mg-800 mg.
[0199] In order to obtain better preventive / therapeutic effects, in some embodiments, the weight of the first RNAi agent administered to the subject is 5 mg-500 mg, and the weight of the second RNAi agent administered to the subject is 5 mg-800 mg.
[0200] In some embodiments, the method further comprises administering to the subject a third RNAi agent, wherein the third RNAi agent comprises one or more third siRNAs and / or one or more third siRNA conjugates, each of the third siRNAs being independently an siRNA capable of inhibiting ANGPTL3 mRNA expression, and each of the third siRNA conjugates comprising a third siRNA group formed from one of the third siRNAs and a conjugated group conjugated thereto.
[0201] In some embodiments, based on the total amount of siRNA and siRNA groups contained in each of the third RNAi agent and the second RNAi agent, the weight ratio of the third RNAi agent to the second RNAi agent administered to the subject is 100: 1-1: 100, for example, 100: 1, 50: 1, 25: 1, 15: 1, 10: 1, 5: 1, 4: 1, 3: 1, 2: 1, 1: 1, 1: 100, 1: 50, 1: 25, 1: 15, 1: 10, 1: 5, 1: 3, 1: 4, 1: 2. In some embodiments, preferably, the weight ratio of the third RNAi agent to the second RNAi agent administered to the subject is 10: 1-1: 10, 5: 1-1: 5, or 2: 1-1: 5.
[0202] In some embodiments, based on the total amount of siRNA and siRNA groups contained in the third RNAi agent, the dose of the third RNAi agent administered to the subject each time is a fixed dose of 1 mg-1000 mg, for example, 1 mg-800 mg, 1 mg-600 mg, 1 mg-500 mg, 1 mg-300 mg, 1 mg-250 mg, or 1 mg-100 mg.
[0203] In some embodiments, based on the total amount of siRNA and siRNA groups contained in each of the third RNAi agents, the dosage of the third RNAi agent administered to the subject each time is 0.5 mg / Kg-10 mg / Kg of the subject's body weight, for example, it can be 0.5 mg / Kg-5 mg / Kg of the subject's body weight, 0.5 mg / Kg-3 mg / Kg of the subject's body weight, 1 mg / Kg-3 mg / Kg of the subject's body weight, or 1 mg / Kg-5 mg / Kg of the subject's body weight.
[0204] The definitions and selection ranges of the first RNAi agent, the second RNAi agent, and the third RNAi agent are the same as those of the first RNAi agent, the second RNAi agent, and the third RNAi agent in the pharmaceutical composition of the present disclosure.
[0205] As used herein, the term "administration / administration" refers to placing an siRNA, pharmaceutical composition and / or siRNA conjugate into a subject's body by a method or approach that at least partially localizes the siRNA, pharmaceutical composition and / or siRNA conjugate to a desired site to produce a desired effect. Routes of administration suitable for the methods of the present disclosure include local administration and systemic administration. In general, local administration results in more siRNA, pharmaceutical composition and / or siRNA conjugate being delivered to a specific site compared to the entire body of the subject; while systemic administration results in the siRNA, pharmaceutical composition and / or siRNA conjugate being delivered to substantially the entire body of the subject. Given that the present disclosure is intended to provide a means for preventing and / or treating pathological conditions or diseases caused by the expression of specific genes in liver cells, in some embodiments, the administration is a method that can deliver the drug to the liver.
[0206] Administration to a subject can be by any suitable route known in the art, including but not limited to oral or parenteral routes, such as intravenous administration, intramuscular administration, subcutaneous administration, transdermal administration, airway administration (aerosol), pulmonary administration, nasal administration, rectal administration and topical administration (including buccal administration and sublingual administration).
[0207] In some embodiments, in order to obtain better prevention / treatment effects, all RNAi agents are administered to the subject in the form of subcutaneous injection. For example, the first RNAi agent, the second RNAi agent, and the third RNAi agent are administered in the form of a uniformly mixed subcutaneous injection.
[0208] In some embodiments, for a single administration, the first RNAi agent and the second RNAi agent are administered to the subject simultaneously, or the first RNAi agent and the second RNAi agent are administered to the subject separately within twenty-four hours.
[0209] In some embodiments, for a single administration, the method comprises administering to the subject the third RNAi agent, wherein the third RNAi agent is administered to the subject simultaneously with the first RNAi agent and the second RNAi agent or sequentially within twenty-four hours.
[0210] In some embodiments, the interval between each administration of the first RNAi agent, the second RNAi agent, and the third RNAi agent is 7 days to 60 weeks, 14 days to 60 weeks, 14 days to 1 year, or 14 days to 2 years. In some embodiments, in order to obtain a better therapeutic effect, the interval between each administration of the first RNAi agent, the second RNAi agent, and the third RNAi agent is 14 days to 1 year, 3 weeks to 1 year, 1 month to 1 year, 2 months to 1 year, 3 months to 1 year, or half a year to 1 year. Specifically, in some embodiments, the interval between each administration of the first RNAi agent, the second RNAi agent, and the third RNAi agent is 14 days, 21 days, 1 month, 2 months, 3 months, half a year, 1 year, or 2 years.
[0211] The present disclosure will be further illustrated below by way of examples, but the present disclosure is not limited thereby.
[0212] Example
[0213] Unless otherwise specified, all reagents and culture media used in the following examples are commercially available products, and nucleic acid electrophoresis, real-time PCR and other operations used are performed according to the methods described in Molecular Cloning (Cold Spring Harbor Laboratory Press (1989)).
[0214] Preparation Example 1 Preparation of the pharmaceutical composition provided by the present disclosure
[0215] 1-1 Preparation of the First and Second siRNA Conjugates in the Pharmaceutical Compositions of the Present Disclosure
[0216] According to the preparation method described in Preparation Example 13 of CN110959011A, a first siRNA conjugate and a second siRNA conjugate were prepared in the form of lyophilized powders, with the only difference being that the sense strand and antisense strand contained in the first siRNA conjugate and the second siRNA conjugate had the sequences shown in Table 4 below, and the sense strand and antisense strand were synthesized separately. Conjugate 1 and Conjugate 2 were diluted to a concentration of 0.2 mg / mL (based on the amount of siRNA groups) using ultrapure water (Milli-Q ultrapure water analyzer, resistivity 18.2 MΩ*cm (25°C)), and molecular weight was determined using liquid chromatography-mass spectrometry (LC-MS, purchased from Waters, model: LCT Premier). The theoretical molecular weight (MW) of the sense strand of the first siRNA conjugate was 7581.42, the measured value was 7581.22, and the theoretical molecular weight of the antisense strand was 6948.55, the measured value was 6948.05; the theoretical molecular weight of the sense strand of the second siRNA conjugate was 7426.26, the measured value was 7425.55, and the theoretical molecular weight of the antisense strand was 7084.88, the measured value was 7084.14. The measured values were consistent with the theoretical values, indicating that the synthesized first siRNA conjugate and the second siRNA conjugate were the target designed double-stranded nucleic acid sequences. The obtained first siRNA conjugate and the second siRNA conjugate have the structure shown in formula (403):
[0217] Table 4 Sequences of the sense and antisense strands in siRNA conjugates
[0218] Among them, the capital letters C, G, U, A, and T represent the base composition of the nucleotide; the lowercase letter m indicates that the nucleotide adjacent to the left of the letter m is a methoxy-modified nucleotide; the lowercase letter f indicates that the nucleotide adjacent to the left of the letter f is a fluorine-modified nucleotide; the underlined letter combination moe indicates that the nucleotide adjacent to the left of the letter combination moe is a ribose 2'-O-methoxyethyl-modified nucleotide; the lowercase letter s indicates that the two nucleotides on the left and right of the letter s are connected by a thiophosphate group; P indicates that the nucleotide to the right of the letter P is a 5'-phosphate nucleotide.
[0219] 1-2 Preparation of the First and Second RNAi Agents in the Pharmaceutical Compositions of the Present Disclosure
[0220] The first siRNA conjugate powder prepared in 1-1 was dissolved in PBS to prepare solutions with concentrations of 0.2 mg / mL and 0.6 mg / mL, respectively, which were recorded as low-concentration first RNAi agent and high-concentration first RNAi agent, respectively.
[0221] The second siRNA conjugate powder prepared in 1-1 was dissolved in PBS to prepare solutions with concentrations of 0.6 mg / mL and 1.2 mg / mL, respectively, which were recorded as low-concentration second RNAi agent and high-concentration second RNAi agent, respectively.
[0222] 1-3 Preparation of the Pharmaceutical Composition of the Present Disclosure
[0223] 0.9 mL of the low-concentration first RNAi agent and 0.9 mL of the low-concentration second RNAi agent were uniformly mixed to prepare a pharmaceutical composition I, wherein the weight ratio of the first RNAi agent to the second RNAi agent was 1:3.
[0224] 0.9 mL of the high-concentration first RNAi agent and 0.9 mL of the low-concentration second RNAi agent were uniformly mixed to prepare a pharmaceutical composition II, wherein the weight ratio of the first RNAi agent to the second RNAi agent was 1:1.
[0225] Pharmaceutical composition III was prepared by uniformly mixing 0.9 mL of the high-concentration first RNAi agent and 0.9 mL of the high-concentration second RNAi agent, wherein the weight ratio of the first RNAi agent to the second RNAi agent was 1:2.
[0226] Experimental Example 1: Activity of the pharmaceutical composition provided by the present disclosure in mice
[0227] Thirty-five female hAPOC3 transgenic mice (species: (C57BL / 6J×CBA / J)F1, grade: SPF, purchased from Besford) were randomly divided into seven groups, with five mice in each group, numbered as Group 1 to Group 7. These mice had severe hypertriglyceridemia and significantly elevated cholesterol.
[0228] The mice in Groups 1 to 7 were respectively medicated according to the dosing schedule in Table 5 below on the day of grouping, and the dosing diary was the first day.
[0229] Table 5. Dosing regimen for mice in groups 1 to 8
[0230] All mice were bled from the anterior orbital cavity on the first day (D1) before dosing, on the eighth day (D8), and on the fifteenth day (D15). After fasting for 4-6 hours, 0.2 mL of blood was collected from the anterior orbital cavity using EDTAK2 anticoagulant blood collection tubes and anesthetized with 70% CO2. The blood was centrifuged at 1800g for 15 minutes at 2-8°C. The supernatant was separated from the plasma and stored at -80°C.
[0231] The obtained plasma samples were sent to Lebo Pharmaceuticals (Shanghai) Co., Ltd. for measurement of plasma TC and LDL-c levels. The normalized values for plasma TC and LDL-c were calculated as (post-dose (D8 or D15) level / pre-dose (D1) level) x 100%. The results for each group are summarized in Table 6 below.
[0232] Table 6 Normalized values of TC and LDL-C levels in mice from Group 1 to Group 8
[0233] As can be seen from the results in Table 6, regarding the changes in TC levels, on the one hand, under the condition that the total dose was 6 mg / Kg, the mice in Group 4, which were given 6 mg / Kg of RNAi agent that inhibits PCSK9 mRNA alone, showed almost no decrease in TC, while the mice in Group 6, which were given the pharmaceutical composition of the present invention (3 mg / Kg each of RNAi agent that inhibits APOC3 mRNA and RNAi agent that inhibits PCSK9 mRNA), showed a TC reduction rate of more than 45% (TC reduction rate = 100% - TC content normalization value); even if the TC reduction rates of the mice in Group 2, which were given RNAi agent that inhibits APOC3 mRNA, and Group 3, which were given RNAi agent that inhibits PCSK9 mRNA, were added together, the TC reduction rate was still less than 45%; under the condition that the total dose was 4 mg / Kg, the mice in Group 1, which were given 1 mg / Kg of RNAi agent that inhibits APOC3 mRNA alone, and Group 3, which were given 3 mg / Kg of RNAi agent that inhibits PCSK9 mRNA, showed no decrease in TC. The maximum total TC reduction rate in mice in Group 3, which was administered with the RNAi agent that inhibits APOC3 mRNA, was 34.9%, while the TC reduction rate in mice in Group 5, which was administered with the pharmaceutical composition of the present invention (1 mg / Kg of RNAi agent that inhibits APOC3 mRNA and 3 mg / Kg of RNAi agent that inhibits PCSK9 mRNA), reached 37.2%. On the other hand, taking the changes in TC levels on the 8th day after administration as an example, under the condition that the total dose was 6 mg / Kg, the TC of Group 4, which was administered with 6 mg / Kg of RNAi agent that inhibits PCSK9 mRNA alone, was not reduced, while Group 6, which was administered with the pharmaceutical composition of the present invention (3 mg / Kg each of RNAi agent that inhibits APOC3 mRNA and RNAi agent that inhibits PCSK9 mRNA), showed a TC reduction rate of 45.6%; and the sum of the TC reduction rates of Group 2, which was administered with RNAi agent that inhibits APOC3 mRNA (3 mg / Kg) and Group 3, which was administered with RNAi agent that inhibits PCSK9 mRNA (3 mg / Kg), was only 33.3%; under the condition that the total dose was 4 mg / Kg, Group 1, which was administered with 1 mg / Kg of RNAi agent that inhibits APOC3 mRNA alone and Group 3, which was administered with 3 mg / Kg of RNAi agent that inhibits PCSK9 mRNA, showed a TC reduction rate of 45.6%. The total TC reduction rate of Group 3, which was administered with RNAi agents that inhibit APOC3 mRNA, was the highest at 34.9%, while the TC reduction rate of Group 5, which was administered with the pharmaceutical composition of the present disclosure (1 mg / Kg of RNAi agents that inhibit APOC3 mRNA and 3 mg / Kg of RNAi agents that inhibit PCSK9 mRNA), reached 37.0%.
[0234] Regarding changes in LDL-c levels, at a total dose of 6 mg / kg, mice in Group 4, which were given a single RNAi agent that inhibited PCSK9 mRNA, showed a maximum LDL-c reduction rate of 43.3% (LDL-c reduction rate = 100% - LDL-c content normalized value), while mice in Group 6, which were given the pharmaceutical composition of the present disclosure, showed an LDL-c reduction rate of up to 72.8%. Furthermore, neither high-dose RNAi agents that inhibited APOC3 mRNA nor high-dose RNAi agents that inhibited PCSK9 mRNA alone could reduce plasma LDL-c levels to below 50%, while mice in Group 5, which were given a low dose (4 mg / kg) of the pharmaceutical composition of the present disclosure, showed an LDL-c reduction rate of up to 67%. Taking the changes in LDL-c levels on the 8th day after administration as an example, under the condition that the total administration dose was 6 mg / Kg, Group 4, which was administered with the RNAi agent that inhibits PCSK9 mRNA alone, showed an LDL-c reduction rate of 41.4%, while Group 6, which was administered with the pharmaceutical composition of the present invention (3 mg / Kg each of the RNAi agent that inhibits APOC3 mRNA and the RNAi agent that inhibits PCSK9 mRNA), showed an LDL-c reduction rate of up to 72.8%.
[0235] The above results show that compared with the first or second RNAi agent alone, the compositions and treatment methods provided by the present disclosure have significantly better lowering effects on both TC levels and LDL-c levels, showing significant synergistic effects. In particular, they show a strong synergistic effect on the reduction of LDL-c levels, which has attracted much attention. Unexpectedly, they have broken through the limit of LDL-c level reduction achieved by administering the first or second RNAi agent alone. The pharmaceutical compositions and treatment methods disclosed herein have good application prospects for preventing and / or treating symptoms or diseases related to hyperlipidemia.
[0236] Some embodiments of the present disclosure are described in detail above. However, the present disclosure is not limited to the specific details of the above embodiments. Within the technical concept of the present disclosure, various simple modifications can be made to the technical solution of the present disclosure, and these simple modifications all fall within the scope of protection of the present disclosure.
[0237] It should also be noted that the various specific technical features described in some of the above embodiments can be combined in any appropriate manner without contradiction. In order to avoid unnecessary repetition, the present disclosure will not further describe various possible combinations.
[0238] In addition, the various embodiments of the present disclosure may be arbitrarily combined, and as long as they do not violate the concept of the present disclosure, they should also be regarded as the contents disclosed by the present disclosure.
Claims
1. A pharmaceutical composition comprising a first RNAi agent and a second RNAi agent, wherein: The first RNAi agent comprises one or more first siRNAs and / or one or more first siRNA conjugates, each first siRNA being independently an siRNA capable of inhibiting APOC3 mRNA, each of the first siRNA conjugates comprising an siRNA group formed by one of the first siRNAs and a conjugated group conjugated thereto; The second RNAi agent comprises one or more second siRNAs and / or one or more second siRNA conjugates, each second siRNA being independently an siRNA capable of inhibiting PCSK9 mRNA, each of the second siRNA conjugates comprising an siRNA group formed by one of the second siRNAs and a conjugated group conjugated thereto; Based on the total amount of siRNA and siRNA groups contained in the first RNAi agent and the second RNAi agent respectively, the weight ratio of the first RNAi agent to the second RNAi agent in the pharmaceutical composition is 10:1-1:
10.
2. The pharmaceutical composition according to claim 1, wherein The weight ratio of the first RNAi agent to the second RNAi agent in the pharmaceutical composition is 5:1-1:
5.
3. The pharmaceutical composition according to claim 2, wherein The weight ratio of the first RNAi agent to the second RNAi agent in the pharmaceutical composition is 2:1-1:
5.
4. The pharmaceutical composition according to claim 1, wherein Based on the total amount of siRNA and siRNA groups contained in the first RNAi agent and the second RNAi agent respectively, in each portion of the pharmaceutical composition, the content of the first RNAi agent is 5 mg-500 mg, and the content of the second RNAi agent is 5 mg-800 mg.
5. The pharmaceutical composition according to claim 4, wherein In each portion of the pharmaceutical composition, the content of the first RNAi agent is 25 mg-250 mg, and the content of the second RNAi agent is 50 mg-500 mg.
6. The pharmaceutical composition according to claim 1, wherein The first RNAi agent and / or the second RNAi agent further contains one or more of a solvent, a pharmaceutically acceptable carrier and an excipient.
7. The pharmaceutical composition according to claim 1, wherein Each first siRNA comprises a sense strand and an antisense strand, each nucleotide in the sense strand and the antisense strand is independently a modified or unmodified nucleotide; the sense strand is 18-23 nucleotides in length, the antisense strand is 18-26 nucleotides in length, the sense strand and the antisense strand are substantially reverse complementary or completely reverse complementary, the first siRNA includes at least one siRNA, the sense strand of the first siRNA has at least 15 consecutive nucleotides consistent with the nucleotide sequence shown in SEQ ID NO:1, or the sense strand has at least 15 consecutive nucleotides consistent with the nucleotide sequence shown in SEQ ID NO:2: 5'-UGGCCUCCCAAUAAAGCUGGACAAGAAGCU-3'(SEQ ID NO:1); 5'-UGCUUAAAAGGGACAGUAUUCUCAGUGCUC-3'(SEQ ID NO:2).
8. The pharmaceutical composition according to claim 7, wherein All nucleotides in the sense strand and the antisense strand are modified nucleotides; from the 5' end to the 3' end, the 7th to 9th nucleotides of the sense strand are 2'-fluoro-modified nucleotides, and from the 5' end to the 3' end, the 2nd, 6th, 14th, and 16th nucleotides of the antisense strand are 2'-fluoro-modified nucleotides, and the nucleotides at other positions of the sense strand and the antisense strand are each independently one of non-fluoro-modified nucleotides. 9 . The pharmaceutical composition of claim 8 , wherein the first siRNA has a sequence as shown in siAPOC3b1-M1SP1 or siAPOC3b3-M1S.
10. The pharmaceutical composition according to claim 1, wherein Each second siRNA comprises a sense strand and an antisense strand, each nucleotide in the sense strand and the antisense strand is independently a modified or unmodified nucleotide; the length of the sense strand is 18-23 nucleotides, and the length of the antisense strand is 18-26 nucleotides. The second siRNA includes at least one siRNA, the sense strand of which is substantially reverse complementary or completely reverse complementary to the antisense strand, and the sense strand of the second siRNA has at least 15 consecutive nucleotides consistent with the nucleotide sequence shown in SEQ ID NO:3: 5'-UUCUAGACCUGUUUUGCUUUUGUAACUUGA-3' (SEQ ID NO:3).
11. The pharmaceutical composition according to claim 10, wherein All nucleotides in the sense strand and the antisense strand are modified nucleotides; from the 5' end to the 3' end, the 7th to 9th nucleotides of the sense strand are 2'-fluoro-modified nucleotides, and from the 5' end to the 3' end, the 2nd, 6th, 14th, and 16th nucleotides of the antisense strand are 2'-fluoro-modified nucleotides, and the nucleotides at other positions of the sense strand and the antisense strand are each independently one of non-fluoro-modified nucleotides.
12. The pharmaceutical composition according to claim 11, wherein The second siRNA has the sequence shown as siPCSKd1-M1S.
13. The pharmaceutical composition according to claim 1, wherein The conjugated group in each of the first siRNA conjugate and the second siRNA conjugate comprises a linker and a pharmaceutically acceptable targeting group, and the first siRNA group or the second siRNA group, the linker and the targeting group are covalently or non-covalently connected in sequence, and each of the targeting groups is selected from a ligand capable of binding to the cell surface ASGPR.
14. The pharmaceutical composition according to claim 13, wherein The first siRNA conjugate and / or the second siRNA conjugate has a structure shown in formula (403): Wherein, Nu represents the first siRNA group or the second siRNA group.
15. The pharmaceutical composition according to claim 1, wherein The first RNAi agent contains only one first siRNA conjugate and / or the second RNAi agent contains only one second siRNA conjugate; the sense strand of the first siRNA is substantially reverse complementary or completely reverse complementary to the antisense strand, and the sense strand of the first siRNA is at least 15 nucleotides consecutively identical to the nucleotide sequence shown in SEQ ID NO:1, or the sense strand of the first siRNA is at least 15 nucleotides consecutively identical to the nucleotide sequence shown in SEQ ID NO:2; the sense strand of the second siRNA is substantially reverse complementary or completely reverse complementary to the antisense strand, and the sense strand of the second siRNA is at least 15 nucleotides consecutively identical to the nucleotide sequence shown in SEQ ID NO:3; 5'-UGGCCUCCCAAUAAAGCUGGACAAGAAGCU-3'(SEQ ID NO:1); 5'-UGCUUAAAAGGGACAGUAUUCUCAGUGCUC-3'(SEQ ID NO:2); 5'-UUCUAGACCUGUUUUGCUUUUGUAACUUGA-3'(SEQ ID NO:3).
16. The pharmaceutical composition according to claim 15, wherein The first RNAi agent contains only one first siRNA conjugate, and the second RNAi agent contains only one second siRNA conjugate.
17. The pharmaceutical composition according to claim 1, wherein The first RNAi agent and the second RNAi agent are present in the form of separate preparations for subcutaneous injection; or, the first RNAi agent and the second RNAi agent are present in the form of a uniform mixture for subcutaneous injection.
18. The pharmaceutical composition according to any one of claims 1 to 17, wherein The pharmaceutical composition further contains a third RNAi agent, which contains one or more third siRNAs and / or one or more third siRNA conjugates, each of which is independently an siRNA capable of inhibiting the expression of ANGPTL3 mRNA, and each of which contains a third siRNA group formed by one of the third siRNAs and a conjugated group conjugated thereto.
19. The pharmaceutical composition according to claim 18, wherein Based on the total amount of siRNA and siRNA groups contained in the third RNAi agent and the second RNAi agent respectively, the weight ratio of the third RNAi agent to the second RNAi agent in the pharmaceutical composition is 10:1-1:
10.
20. The pharmaceutical composition of claim 18 or 19, wherein each of the third siRNAs comprises a sense strand and an antisense strand, and each nucleotide in the sense strand and the antisense strand is independently a modified or unmodified nucleotide; the length of the sense strand is 18-23 nucleotides, and the length of the antisense strand is 18-26 nucleotides, and the third siRNA comprises at least one siRNA, wherein the sense strand and the antisense strand of the siRNA are substantially reverse complementary or completely reverse complementary, and the sense strand of the third siRNA has at least 17 consecutive nucleotides consistent with the nucleotide sequence shown in SEQ ID NO:4: 5'-AGCCAAAAUCAAGAUUUGCUAUGUUAGACG-3' (SEQ ID NO:4).
21. The pharmaceutical composition according to claim 20, wherein The third siRNA has the sequence shown in siANGa1-M1S or siANGa1-M2S.
22. Use of the pharmaceutical composition according to any one of claims 1 to 21 in the preparation of a medicament for treating and / or preventing diseases or symptoms associated with hyperlipidemia.
23. The use according to claim 22, wherein The disease or symptom associated with hyperlipidemia is selected from one or more of hypercholesterolemia, hypertriglyceridemia, combined hyperlipidemia and familial hypercholesterolemia.
24. A method for treating and / or preventing a disease or symptom associated with hyperlipidemia, the method comprising administering an effective amount of a first RNAi agent and a second RNAi agent to a subject in need thereof, wherein the first RNAi agent comprises one or more first siRNAs and / or one or more first siRNA conjugates, each first siRNA is independently an siRNA capable of inhibiting APOC3 mRNA, and each first siRNA conjugate comprises an siRNA group formed by one of the first siRNAs and a conjugated group conjugated thereto; The second RNAi agent comprises one or more second siRNAs and / or one or more second siRNA conjugates, each second siRNA is independently an siRNA capable of inhibiting PCSK9 mRNA, and each second siRNA conjugate comprises an siRNA group formed by one of the second siRNAs and a conjugated group conjugated thereto; Based on the total amount of siRNA and siRNA groups contained in each of the first RNAi agent and the second RNAi agent, the weight ratio of the first RNAi agent and the second RNAi agent administered to the subject is 10:1-1:
10.
25. The method of claim 24, wherein: The weight ratio of the first RNAi agent and the second RNAi agent administered to the subject is 5:1-1:
5.
26. The method of claim 25, wherein: The weight ratio of the first RNAi agent to the second RNAi agent administered to the subject is 2:1-1:
5.
27. The method of claim 24, wherein: Based on the total amount of siRNA and siRNA groups, the dosage of the first RNAi agent administered to the subject each time is 0.5 mg / Kg-5 mg / Kg of the subject's body weight, and the dosage of the second RNAi agent administered to the subject each time is 0.5 mg / Kg-9 mg / Kg of the subject's body weight.
28. The method of claim 27, wherein: The dosage of the first RNAi agent administered to the subject each time is 1 mg / Kg-3 mg / Kg of the subject's body weight, and the dosage of the second RNAi agent administered to the subject each time is 3 mg / Kg-9 mg / Kg of the subject's body weight.
29. The method of claim 24, wherein: The dosage of the first RNAi agent administered to the subject each time is a fixed dosage of 5 mg-500 mg, and the dosage of the second RNAi agent administered to the subject each time is a fixed dosage of 5 mg-800 mg.
30. The method of claim 29, wherein: The dose of the first RNAi agent administered to the subject each time is a fixed dose of 25 mg-250 mg, and the dose of the second RNAi agent administered to the subject each time is a fixed dose of 50 mg-500 mg.
31. The method of claim 24, wherein: Each nucleotide in the sense strand and the antisense strand is independently a modified or unmodified nucleotide; wherein the length of the sense strand is 18-23 nucleotides, the length of the antisense strand is 18-26 nucleotides, the sense strand and the antisense strand are substantially reverse complementary or completely reverse complementary, the first siRNA includes at least one siRNA, the sense strand of the first siRNA has at least 15 consecutive nucleotides consistent with the nucleotide sequence shown in SEQ ID NO:1, or the sense strand has at least 15 consecutive nucleotides consistent with the nucleotide sequence shown in SEQ ID NO:2: 5'-UGGCCUCCCAAUAAAGCUGGACAAGAAGCU-3'(SEQ ID NO:1); 5'-UGCUUAAAAGGGACAGUAUUCUCAGUGCUC-3'(SEQ ID NO:2).
32. The method of claim 31, wherein: All nucleotides in the sense strand and the antisense strand are modified nucleotides; in the direction from the 5' end to the 3' end, the 7th to 9th nucleotides of the sense strand are 2'-fluoro-modified nucleotides, and in the direction from the 5' end to the 3' end, the 2nd, 6th, 14th, and 16th nucleotides of the antisense strand are 2'-fluoro-modified nucleotides, and the other nucleotides in the antisense strand are each independently one of non-fluoro-modified nucleotides.
33. The method of claim 32, wherein: The first siRNA has the sequence shown in siAPOC3b1-M1SP1 or siAPOC3b3-M1S.
34. The method of claim 24, wherein: Each second siRNA comprises a sense strand and an antisense strand, each nucleotide in the sense strand and the antisense strand is independently a modified or unmodified nucleotide; the sense strand is 18-23 nucleotides in length, the antisense strand is 18-26 nucleotides in length, the sense strand is substantially reverse complementary to the antisense strand or completely reverse complementary, the second siRNA includes at least one siRNA, the sense strand of the second siRNA has at least 15 consecutive nucleotides consistent with the nucleotide sequence shown in SEQ ID NO:3: 5'-UUCUAGACCUGUUUUGCUUUUGUAACUUGA-3' (SEQ ID NO:3).
35. The method of claim 34, wherein: All nucleotides in the sense strand and the antisense strand are modified nucleotides; from the 5' end to the 3' end, the 7th to 9th nucleotides of the sense strand are 2'-fluoro-modified nucleotides, and from the 5' end to the 3' end, the 2nd, 6th, 14th, and 16th nucleotides of the antisense strand are 2'-fluoro-modified nucleotides, and the nucleotides at other positions of the sense strand and the antisense strand are each independently one of non-fluoro-modified nucleotides.
36. The method of claim 35, wherein: The second siRNA has the sequence shown as siPCSKd1-M1S.
37. The method of claim 24, further comprising administering to the subject a third RNAi agent, wherein the third RNAi agent comprises one or more third siRNAs and / or one or more third siRNA conjugates, each third siRNA being independently a siRNA capable of inhibiting ANGPTL3 mRNA expression, and each of the third siRNA conjugates comprising a third siRNA group formed by one of the third siRNAs and a conjugated group conjugated thereto.
38. The method of claim 37, wherein: Based on the total amount of siRNA and siRNA groups contained in the third RNAi agent and the second RNAi agent respectively, the weight ratio of the third RNAi agent to the second RNAi agent administered to the subject each time is 10:1-1:
10.
39. The method of claim 37, wherein: Each of the third siRNAs comprises a sense strand and an antisense strand, each nucleotide in the sense strand and the antisense strand is independently a modified or unmodified nucleotide; the length of the sense strand is 18-23 nucleotides, the length of the antisense strand is 18-26 nucleotides, the sense strand and the antisense strand are substantially reverse complementary or completely reverse complementary, the third siRNA includes at least one siRNA, the sense strand of the third siRNA has at least 15 consecutive nucleotides consistent with the nucleotide sequence shown in SEQ ID NO:4: 5'-AGCCAAAAUCAAGAUUUGCUAUGUUAGACG-3' (SEQ ID NO:4).
40. The method of claim 39, wherein: The third siRNA has the sequence shown in siANGa1-M1S or siANGa1-M2S.
41. The method of claim 24, wherein: The first RNAi agent and the second RNAi agent are administered to the subject simultaneously, or the first RNAi agent and the second RNAi agent are administered to the subject separately and sequentially within twenty-four hours.
42. The method of claim 37, wherein: The method further comprises administering an effective amount of a third RNAi agent to the subject, wherein the third RNAi agent is administered to the subject simultaneously with the first RNAi agent and the second RNAi agent or sequentially within twenty-four hours.
43. The method of claim 24 or 37, wherein: All RNAi agents were administered to the subject by subcutaneous injection.
44. The method of any one of claims 24 to 43, wherein: The disease or symptom is selected from one or more of hypercholesterolemia, hypertriglyceridemia, combined hyperlipidemia and familial hypercholesterolemia.
Citation Information
Cited By
Combinations of antisense agents, pharmaceutical compositions and methods of use
WO2026133250A1
Combinations of antisense agents, pharmaceutical compositions and methods of use
WO2026133251A1
Combinations of antisense agents, pharmaceutical compositions and methods of use
WO2026133253A1
